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Abstract 
Since the early 1990’s HIV/AIDS emerged as a global health pandemic, with sub-Saharan Africa the 
hardest hit. While the successful roll-out of antiretroviral (ARV) therapy provided significant relief to 
HIV-positive individuals, such treatment can also elicit damaging side-effects. Here especially HIV 
protease inhibitors (PIs) are implicated in the onset of cardiometabolic complications such as type-2 
diabetes and acute myocardial infarction. As the underlying mechanisms driving PI-mediated side-
effects remain unclear, this study set out to investigate this intriguing question by employing a rat 
model of chronic PI treatment (6 months). In addition, various co-treatments (Resveratrol, Aspirin, 
Vitamin C) were evaluated to ascertain whether such a therapeutic strategy may blunt PI-induced 
side-effects. Body weights and weight gains, blood metabolite levels, echocardiography and cardiac 
mitochondrial respiration were assessed. Our data reveal that after 2 months of PI treatment there 
were no significant changes for the various parameters evaluated in this study. However, after 4 
months Vitamin C co-treatment ameliorated the PI-induced decrease in body weight, while it also 
blunted the PI-mediated inhibition of mitochondrial respiration. Aspirin co-treatment also improved 
mitochondrial respiration while this effect was not observed with Resveratrol. After 6 months of PI 
treatment all interventions prevented the PI-induced increase in body weights, while Aspirin and 
Vitamin C prevented the PI-induced increase in heart weight. At the later time point mitochondrial 
respiration was, unlike at the 4 month time point, not affected by PI treatment. However, 
Resveratrol co-treatment significantly increased mitochondrial respiration. This study demonstrates 
that early PI-mediated perturbations include alterations in body weights and inhibition of 
mitochondrial respiration. However, no significant changes were found for heart function or blood 
metabolites. Our findings show that the co-treatments triggered beneficial outcomes by reversing 
weight changes and enhancing mitochondrial respiratory function. As the co-treatments are already 
well-known and approved therapeutic agents, we are of the opinion that this study provides 
significant impetus to test such compounds to establish whether our basic findings can be 
successfully translated into the clinical setting to eventually improve the overall well-being of HIV-
positive patients. 
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Abstrak 
Sedert die vroeë 1990’s het HIV/VIGS ‘n globale pandemie geword, met Sub-Sahara Afrika veral 
ernstig getref. Alhoewel die suksesvolle uitreiking van antiretrovirale (ARV) terapie al talle HIV-
positiewe individue gehelp het, kan hierdie middels skadelike newe-effekte veroorsaak. Meer 
spesifiek, HIV protease inhibitore (PIs) word geïmpliseer in die ontwikkeling van kardio-metaboliese 
komplikasies soos tipe-2 diabetes en miokardiale infarksies. Aangesien die meganismes van die 
komplikasies nie bekend is nie, is hierdie studie gemik daarop om hierdie meganismes te ondersoek. 
Dit is uitgevoer deur n rot-model van kroniese PI behandeling (6 maande). Addisioneel is verskeie 
intervensies  (Resveratrol, Aspirien, Vitamien C) getoets om te ondersoek of sulke terapeutiese 
middels die PI-geïndiseerde newe-effekte kan beveg. Liggaamsgewig en gewigsvermeerdering, bloed 
metaboliet vlakke, eggokardiografie en kardiale mitochondriale respirasie is geassesseer. Ons data 
wys na 2 maande van PI behandeling geen beduidende verskille in die getoetste parameters nie. Na 
4 maande het mede-behandeling van Vitamien C egter die PI-geïnduseerde gewigsverlies voorkom, 
sowel as die PI-geïnduseerde inhibisie van mitochondriale respirasie. Aspirien mede-behandeling het 
ook mitochondriale respirasie verbeter, maar hierdie effek is nie waargeneem met Resveratrol 
mede-behandeling nie. Na 6 maande van PI behandeling het al die intervensies daarin geslaag om 
die PI geïnduseerde gewigsvermeerdering te voorkom. Aspirien en Vitamien C was ook suksesvol om 
die PI geïnduseerde gewigsvermeerdering te voorkom. Aspirien en Vitamien C het ook suksesvol die 
PI geïnduseerde hartgewig vermeerdering voorkom. Na 6 maande was mitochondriale respirasie nie 
deur PI behandeling geaffekteer nie. Resveratrol mede-behandeling het wel mitochondriale 
respirasie beduidend verhoog na 6 maande van behandeling. Hierdie studie demonstreer dat 
veranderinge in liggaamsgewig en mitochondriale respirasie deel uitmaak van vroeë PI geïnduseerde 
newe-effekte. Daar is egter geen veranderinge in hart funksie of bloed metaboliete waargeneem nie. 
Ons bevindings toon dat die mede-behandelinge voordelige resultate gelewer het deur 
liggaamsgewig veranderinge om te keer en mitochondriale respirasie te verbeter. Aangesien hierdie 
mede-behandelinge reeds welbekend en goedgekeurde terapeutiese middels is, glo ons dat hierdie 
studie goeie rede lewer om meer toetse op hierdie middels te doen. Dit kan gedoen word om vas te 
stel of ons basiese bevindings getransleer kan word in die kliniese omgewing om eventueel die 
gesondheid van HIV-pasiënte te verbeter. 
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 1.1.1. HIV: a global health concern 
 
HIV has become a global pandemic over the last 30 years, affecting an estimated 34 million people at 
the end of 2010, of which 2.7 million were children under the age of 15 (WHO progress report, 
2011). HIV began as a relatively insignificant disease in the 1980s, but escalated to become one of 
the leading causes of deaths and disease burdens worldwide (Ortblad et al, 2013; Rosas et al, 2013).  
The number of people newly infected every year remains remarkably high, with a staggering 2.2 
million new HIV infections in 2010, and a particular concern is that 390 000 of newly infected 
individuals were children (WHO progress report, 2011).  
 
During 2005, the annual global mortality rate from AIDS-related deaths peaked at  2.2 million. Since 
then, this has stabilized and begun to decline. At the end of 2010 the number decreased to an 
estimated 1.8 million. There were also approximately 250 000 less AIDS-related deaths among 
children at the end of 2010, a 20% decrease since 2005 (WHO progress report, 2011). 
 
The rate of new HIV infections is also declining; however, this trend is dependent on the region of 
focus.  For example, in Sub-Saharan Africa an 
estimated 1.9 million people were newly 
infected in 2010. Although this appears relatively 
large it represents a decrease of 16% when 
compared to the 2.2 million new infections 
during 2001, and a 27% decrease when 
compared to 1996 and 1998 when the incidence 
of HIV peaked in the region of sub-Saharan Africa 
(WHO progress report, 2011).  
 
As indicated, this trend of decreasing rate of 
infection is not universal, e.g. new HIV infections 
in the Middle East and Northern Africa increased 
by  72% from 2001 to 2010. The same trend of 
increased number of new infections is occurring 
in Eastern Europe and Central Asia since 2008 
Figure 1.1. Graph depicts the declining number of 
HIV-infected individuals as ART roll-out increases 
worldwide (WHO Progress report 2011: Global 
HIV/AIDS response). 
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(UNAIDS and WHO, AIDS epidemic update, 2009). Such trends not only differ regarding new 
infections, but also in terms of AIDS-related deaths.  
 
For example, in sub-Saharan Africa the number of AIDS-related deaths has stabilized, whereas for 
Eastern Europe and Central Africa it increased from  7 800 in 2001 to  90 000 in 2010, more than a 
10-fold increase. The Middle East and Northern Africa follows a similar trend, with a 60% increase in 
AIDS-related deaths from 2001 to 2010 (WHO progress report, 2011). 
 
Why are there differences in HIV infections and AIDS-related deaths between regions? This is 
possibly due to the availability of HIV testing, prevention methods and counselling in specific regions 
or countries, but more importantly it can be  attributed to the supply and availability of antiretroviral 
(ARV) medicine, as demonstrated  in Figure 1 (WHO progress report, 2011).  
 
 1.1.2. Antiretroviral therapy: a lifeline for the HIV infected 
 
It is estimated that 1 million of the 6 million HIV-positive persons in South Africa received 
antiretroviral therapy (ART) by the end of 2009 (Epidemiological facts sheet on HIV and AIDS, 2008; 
STATSSA mid-year population estimates, 2012). The WHO estimates that this resulted in a 707 000 
life years gained between 1996 and 2009 in this population (WHO progress report, 2011). The life 
years gained was achieved by the initiation of combination ARV treatment in 1996 which brought 
about a revolution in the treatment of HIV.  
 
The above mentioned treatment regime changed the lives of those affected by the virus, but only in 
high-income countries. Even though 90% of the global HIV burden was concentrated in the low- and 
middle-income countries and regions, very few ARVs were available in such burdened areas. 
However, this problem of ARV availability changed in July 2000 at the XIII International AIDS 
Conference (Durban, South Africa) where activists, community leaders, scientists and health care 
providers joined forces to demand global access to treatment for those desperately in need of this 
life saving treatment (WHO progress report, 2011).  
 
Within months the call was answered by some global initiatives, including the Global Fund to Fight 
AIDS and the United States President’s Emergency Plan for AIDS Relief. ARV roll-out began to 
increase in the regions and countries most burdened by HIV (Goal 6: Combat HIV/AIDS, malaria and 
other diseases, 2000).  By the end of 2003, 400 000 HIV-positive individuals in low- and middle-
income class countries received ART. The number of individuals who received ART has since 
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increased exponentially with 6.6 million HIV-positive persons now receiving the lifesaving ART 
globally. The increased availability of ART has led to a global decrease in AIDS-related deaths, and 
also significantly decreased the number of newly-infected cases, when compared to earlier 
predictions made (WHO progress report, 2011).  
 
1.1.3. South Africa severely burdened by HIV/AIDS 
 
In the same country where this unique feat of global health care was initiated, the HIV burden is 
particularly high. Since 1990 the prevalence of HIV in South Africa has steadily increased. During 
2006 it was estimated that South Africa had just under 6 million HIV infected people; approximately 
17% of the adult population, making it the country with the most HIV infected people in the world 
(STATSSA, mid-year population estimates, 2012; WHO progress report, 2011; USAID HIV/AIDS Health 
Profile, 2012).  South Africa is also burdened with a staggering 350 000 AIDS-related deaths annually, 
placing a large strain on both economic and social growth (STATSSA, mid-year population estimates, 
2012). Following world trends in general, however, there has been a decline in both the number of 
new infections and AIDS-related deaths since 2005 (STATSSA, mid-year population estimates, 2012).  
These statistics coincides with the nation-wide ARV roll-out that began in 2003. 
 
Another success story in the fight against HIV in South Africa is the prevention of mother-to-child 
transmission (PMTCT) during birth and breast feeding. Since the start of this initiative in 2003, the 
number of infections transmitted in this manner has decreased to  4%, which is encouraging (USAID 
HIV/AIDS Health Profile, 2012). The success can be largely attributed to the combination of HIV-
testing of majority of pregnant women in clinics for HIV and more importantly, using ARV 
anaphylaxis in new-borns (Kesho Bora study group, 2011), as well as treating an estimated 95% of 
pregnant women with HIV with ART (STATSSA, mid-year population estimates, 2012; USAID 
HIV/AIDS Health Profile, 2012).  
 
According to the World Health Organization (WHO), only 36% of infected individuals are eligible for 
ART (based on the WHO guidelines) which will be briefly discussed later (WHO progress report, 
2011). Although the coverage is very low, there are programs in place to increase the number of 
individuals receiving treatment, as well as improving the treatment regimens (National Strategic 
Plans for HIV, STIs and TB, 2011). Even with these programs in place, adherence to treatment 
regimens remains a major problem in the fight against HIV/AIDS. This, however, will be discussed at 
a later stage.  
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1.1.4. The HIV life cycle and its effects on health 
 
 To understand the treatment regimens and the improvements achieved over the years, the HIV life 
cycle (Fig. 2) will be briefly discussed as this will allow for a better understanding of the mechanisms 
and location of ARV functioning. The different classes of ARVs will then be discussed.  
 
HIV is a retrovirus, consisting of a single strand RNA encapsulated in envelope proteins (Frankel and 
Young, 1998). The infective virion binds/fuses to a host cell and injects its genetic material into the 
host (Ferguson et al, 2002). Once inside the host cell, the RNA strand is reverse transcribed to 
double-stranded DNA, which becomes integrated into the host DNA, and subsequently transcribed 
(Ferguson et al, 2002; Sierra et al, 2005). The host cell then functions as a ‘HIV factory’, churning out 
virions by the millions. The HIV genome encodes for 8 proteins that are necessary for viral DNA 
replication, splicing and assembling of the newly formed viral proteins to produce new, infective 
virions (Teixeira et al, 2011).  
 
These proteins do, however, need to be primed by the viral protease enzyme before it can be used 
for the production of new virions (Frankel and Young, 1998). It is of interest to note that at this stage 
Figure 1.2. A simplified representation of the viral life cycle: ①Once the virus binds to 
the host cell, the viral RNA is injected into the cytoplasm. ②Here it is reverse transcribed 
into DNA through the viral enzyme, reverse transcriptase. ③This viral DNA is then 
integrated into the host DNA and transcribed, producing new viral RNAs and proteins. 
④These get primed by the viral protease enzyme to produce mature proteins, ⑤which 
are assembled to produce new, infective virions (Adapted from Sierra et al, 2005). 
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some of these viral proteins can directly trigger serious detrimental effects on human health 
(Cummins and Badley, 2010). For example, Trans-activator of transcription (Tat) is implicated in 
many HIV-related symptoms, including from toxic effects on the cardiovascular, renal, hepatic and 
nervous systems (Pugliese et al, 2004; Johri et al, 2011). Envelope glycoprotein 120 (GP120) is 
another protein that can induce severe cardio-toxic effects in vitro (Coopusamy, 2010). This provides 
evidence that the virus is able to exert direct effects on cells and tissues through the proteins it 
produces, which results in various systemic complications (Cummins and Badley, 2010).  
 
However, it is also postulated that the above-mentioned symptoms can occur or be exacerbated due 
to persistent immune activation and inflammation caused by the virus (Ho and Hsue, 2008). These 
findings can provide an explanation for the rapid progression of cardiovascular diseases (CVD) that 
can often present in HIV-positive patients. Such patients present with constant pro-atherogenic 
inflammation which is a well-known risk factor for development of CVD (Hober et al, 1989; Wolf et 
al, 2002; Stein et al, 2005, Ho and Hsue, 2008).  
 
HIV thus seems to be causally associated with heart disease, even after controlling for age and 
traditional cardiovascular risk factors (Kaplan et al, 2008). It is important to note that the risk of 
developing cardiovascular complications is higher in untreated, compared to treated HIV-positive 
individuals (White, 2001; Wolf et al, 2002; Ho and Hsue, 2008). It is therefore evident that ART leads 
to increased life expectancy and decreased risk of developing CVD, and possibly hepatic, renal and 
nervous system complications as well (Vervoort et al, 2007; Tebas et al, 2008). 
 
1.1.5. Different classes of ARVs available 
 
ARVs all function to decrease the amount of infectious virions in the blood. There are different 
classes of the drugs which work at different stages of the viral lifecycle as seen in Figure 2. The 
classes of drugs are as follows: Fusion and entry inhibitors, reverse transcriptase inhibitors, integrase 
inhibitors, and protease inhibitors. Fusion and integrase inhibitors are not commonly used in low-
income countries, thus we will only be discussing reverse transcriptase inhibitors (NRTIs and 
NNRTIs), and more of greater relevance to this study, protease inhibitors (PIs). 
 
Currently these drugs are prescribed in combinations of two or three, and are referred to as ‘highly 
active antiretroviral therapy’ (HAART). The combined prescription allows for the drugs to work 
synergistically and inhibit the viral life cycle at different stages, thus not only rendering the 
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treatment more effective, but also decreasing the chances of developing drug resistance (Ammassari 
et al, 2002).  
The choice of combination is based on various parameters which will not be discussed in detail here 
(WHO progress report, 2011). These parameters include patient treatment history, co-infections, 
response to drugs and ART availability. The general rule of thumb is if a patient is treatment-naïve, 
first line therapy is appointed. First line therapy generally consists of two nucleoside reverse-
transcriptase inhibitors (NRTIs) and one non-nucleoside reverse-transcriptase inhibitor (NNRTI).  
 1.1.6. Treatment regimens employed in South Africa 
 
The drugs currently available in South Africa are:  
Zidovudine (AZT); Stavudine (D4T); Didanosine (ddl); Lamivudine (3TC); Abacavir (ABC); 
Emitricitabine (FTC); Tenofovir (TDF) as NRTIs, with Nevirapine (NVP) and Efavirenz (EFV) as NNRTIs 
(The South African Antiviral National Department of Health, 2010).  
 
Patients are started on first-line therapy according to the following WHO recommendations (WHO 
progress report, 2011): 
 HIV-positive patients  displaying a  CD4+ count < 350 cells/mm3 irrespective of clinical 
symptoms  
 
 CD4+ testing required to identify if patients with HIV and WHO clinical stage 1 or 2 
diseases need to start antiretroviral treatment  
 
 HIV-positive patients with HIV and WHO clinical stage 3 or 4, irrespective of CD4 count 
 
 Pregnant women with a CD4+ count < 350 cells/mm3. If CD4+ counts > 350 cells/mm3, 
ARV prophylaxis is initiated after first trimester to avoid mother-to-child transmission 
 
1.1.7. The pros and cons of first-line therapy 
 
Thus first-line therapy is initiated when the host’s CD4+ count drops below 350.  The starting CD4+ 
value was initially < 250. It has since been determined that earlier initiation of HAART leads to better 
treatment outcome (both short- and long-term) (Jani et al, 2010; WHO progress report, 2011). Since 
the new recommendation has been adapted, a better outcome is expected for the treated 
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individuals, but it does raise a serious statistical and logistical problem: with the higher starting CD4+ 
value, the number of eligible individuals increased while ARV availability did not match this increase. 
These findings translate to a decrease in ART coverage, which greatly affects the efficacy of such 
treatment in the long-term battle against HIV/AIDS (UNAIDS South Africa: Country Situation, 2008; 
Colvin et al, 2010). 
 
Although first-line therapy is very successful and is vital in improving the HIV/AIDS situation in many 
countries, its success however comes at a cost (Deeks and Phillips, 2009).  We will initially discuss the 
NNRTIs to further elucidate this point. NNRTIs inhibit the viral reverse transcriptase enzyme (RTE) by 
binding and inactivating the enzyme. NNRTIs have high specificity and are excellent inhibitors of RTE 
activity, but are notorious for triggering rapid development of resistance (Nunberg et al, 1991; 
Richman et al, 1991; Mellors et al, 1992; Schinazi et al, 1997.  
 
Such drugs, if used alone, or if drug adherence of triple therapy is not ideal, can lead to treatment 
failure in patients (discussed later) with detrimental consequences. It is thus important to monitor 
patient health over the course of treatment to ensure viral suppression is successful (WHO progress 
report, 2011).  
 
NRTIs on the other hand operate by resembling natural nucleosides but do not contain free 3’ 
hydroxyl groups (Wright and Brown, 1990; White, 2001). Once the NRTIs are added to the DNA chain 
the next nucleoside cannot bind due to the lacking 5′–3′ phosphodiester bond needed to extend the 
DNA chain. Termination occurs and the viral proteins are rendered unusable (White, 2001). This 
termination causes the potential risk of inhibiting human DNA polymerase activity, leading to chain 
termination in host DNA. 
 
Fortunately there are significant differences between the viral and host enzymes to ensure selective 
inhibition of the viral DNA polymerase (Wright and Brown, 1990; White, 2001). For example, DNA 
polymerase alpha, the main enzyme for DNA replication in humans, appears to be unaffected by the 
NRTI treatment (Lund et al, 2007). However, the activity of related isoforms, i.e. DNA polymerases 
beta and gamma decreased with NRTI treatment (Lund et al, 2007).  DNA polymerase beta functions 
to synthesize short sections of DNA as part of a group of enzymes involved in DNA repair. The clinical 
significance of its down-regulation is still unclear. It should be noted that the HIV Tat protein induces 
the opposite effect and increases its expression (Cheng et al, 1990; Srivastava et al, 2001).  
 
DNA polymerase gamma on the other hand is involved in mitochondrial DNA replication and if 
decreased this affects mitochondrial functioning and can lead to a variety of downstream effects 
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(Cheng et al, 1990). Such drugs are therefore notorious for inducing severe side-effects which are 
believed to be associated with impaired mitochondrial function, leading to insufficient energy 
production and resulting in subsequent cellular dysfunction (White, 2001; Gardner et al, 2013).  
The side-effects of the older generation NRTI treatments were rather lethal, but have since been 
improved with newer drug class generations (Snedecor et al, 2013; Gupta et al, 2013). For example, 
earlier clinical studies showed patients exhibiting anemia and neutropenia when treated with NRTIs. 
In addition to these earlier clinical studies in vitro studies conducted on murine bone marrow 
progenitor cell lines confirmed toxic side-effects observed in patients (Luster et al, 1989).  When 
neuronal cell models were later employed, ddI and d4T elicited toxicity, whereas AZT and 3TC did 
not - again echoing clinical findings (Cui et al, 1997). These in vitro and clinical studies are the reason 
why most patients are started on AZT and 3TC as NRTI backbones for HAART.   
 
Although cell-based studies with AZT and 3TC did not induce toxicity it does not imply that there are 
no other side-effects involved.  This claim is supported by clinical observations that range from 
simple nausea and vomiting, to more serious health issues such as liver cirrhosis and kidney damage 
(White, 2001). Such side-effects (both minor and major) are also part of the reason why many of 
ARV treatment regimens fail, since individuals feel too ill to continue treatment (Carr and Cooper, 
2000; Hawkins, 2006).  
 
1.1.8. Drug adherence affects treatment outcomes 
 
The efficacy of ART is determined by circulating viral load (VL). Thus HIV-positive patients on ART 
require a VL test every 6 months to ensure the effectiveness of their treatment. If a patient’s VL is 
persistently higher than 5000 copies/ml, it is considered as a treatment failure (WHO progress 
report, 2011).  If VL is not available, immunological criteria are used to confirm clinical failure (WHO 
progress report, 2011).  
 
Treatment failure can occur due to a drug being ineffective in an individual. Ineffective treatment 
usually occurs when drug adherence is low, since the drugs’ steady state concentrations never reach 
their effective levels (Doyle and Geretti, 2012). Patients are therefore required to bring their ARVs 
with them when they visit clinics to evaluate drug adherence (National Department of Health, 2013).  
 
Since many of the HIV-infected individuals in South Africa live in rural areas, far from clinics or ART 
distribution centres, drug adherence is consistently low (Epidemiological facts sheet on HIV and 
AIDS, 2008). Walking is often the only mode of transport for many in such regions and during winter 
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months or bad weather many simply do not go for their check-ups (Essop and Nell, unpublished data 
for Cape Winelands region).  
 
The above mentioned logistical problems therefore pose a serious risk for patient care, both short 
and long-term.  Also, ARV side–effects are another important reason for poor drug adherence. Once 
first-line treatment is considered ‘failed’ or the patient’s drug adherence is < 90%, it is 
recommended that second-line therapy be initiated as soon as possible to avoid disease progression 
(WHO progress report, 2011).  
 
1.1.9. Second-line therapy might be the answer in low-income regions 
 
Second-line therapy consists of a boosted PI (explained later) plus two NRTIs. The drugs currently 
employed in South African clinics are Alluvia as a PI, and Zidovudine (AZT) and lamivudine (3TC) as 
the NRTI backbone (National Department of Health, 2010). The NRTI backbone is used to improve 
treatment efficacy as well as to ensure that the patient does not develop drug resistance. It has been 
found that boosted PI treatment has less chance for development of resistance in scenarios of low 
drug adherence (Paterson et al, 2000; Masquelier et al, 2005; Shuter, 2007).  
 
Protease inhibitors function, as the name implies, by inhibiting the HIV protease enzyme (Fig. 2). The 
protease enzyme is essential in the viral life cycle since it is required for the cleaving of the newly 
formed proteins to create mature viral proteins (Frankel and Young, 1998). Once it is bound and 
inhibited by the drug it cannot function and thus the viral life cycle is halted because new virions 
cannot be assembled. Boosted PIs have become the choice of clinicians across the globe, since it is 
more effective at maintaining viral copies < 400 per millilitre than a single PI alone. The term 
‘boosted’ merely implies that the PIs are given in combination, usually with Ritonavir.  
 
Ritonavir is not the ideal PI for managing viral suppression alone. Ritonavir is however a potent 
inhibitor of the CYP3A enzyme. The latter enzyme is required for the metabolism of other PIs. The 
inhibition of CYP3A by Ritonavir allows more active PIs like Lopinavir to be available at higher 
circulating concentrations for longer durations.  The use of boosted PIs has been demonstrated to be 
successful in a number of studies over the past decade (Zeldin, 2004; Bierman, 2010; Siripassorn, 
2010).  
 
In fact, boosted PI treatment is so effective that it can be used successfully as monotherapy. For 
example, in a 96-week analysis of Lopinavir-Ritonavir monotherapy versus normal firstline therapy 
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(two NRTIs + one NNRTI), PI monotherapy was not inferior to triple therapy (two NRTI’s + one 
NNRTI). Interestingly enough it was observed that adverse events leading to discontinuation of 
treatment was significantly lower with PI monotherapy (Pulido et al, 2008; Arribas et al, 2009). In 
South African clinics boosted PIs also play an additional important role since it makes up part of first 
line therapy in pediatric regimens up to the age of three (National Department of Health, 2013). 
 
Second-line therapies containing boosted PIs are therefore very important and beneficial treatment 
regimens. It is especially important in South Africa and other low-income countries because it 
provides long-lasting protection against HIV disease progression (Scherrer et al, 2013). Although 
second-line ART increased life expectancy and quality of life for many HIV-positive individuals, it 
does come at a cost. Side-effects occur with the use of boosted PIs just as they do with first-line 
therapy ARVs (White, 2001). For example, patients on PI-containing second-line ART can develop 
weight gain, lipodystrophy, metabolic syndrome, diabetes and CVD (Duong et al, 2001; Friis-Møller 
et al, 2007; Friis-Møller, 2010; Kumar, 2004; Lee et al 2004; Martinez and Gatell, 1998; Worm et al, 
2010; Zeldin and Petruschke, 2004).  
 
Side-effects such as mentioned above, occur at varying times in different patients. In some cases 
however, many of these side-effects (including heart diseases) have been observed to occur 
relatively early after initiating PI regimens (Friis-Møller et al, 2007). This early occurrence of side-
effects does not correlate with the normal disease progression of HIV or CVD. These observations 
imply that PI treatment is implicated in the development of these serious side-effects. Since the 
emergence of such side-effects, studies attempted to elucidate the underlying mechanism whereby 
this occurs.  
 
 1.1.10. Possible mechanisms of Protease Inhibitor induced side-effects 
 
Although the mechanisms are still relatively unclear, the duration of PI treatment plays an important 
role in its detrimental effects (Friis-Møller et al, 2007; Friis-Møller, 2010). The longer treatment on 
second-line therapy continues, the worse the clinical outcome of the patient becomes.  For example, 
Friis-Møller and colleagues (2007) (Fig. 3), found that the risk for cardiovascular events increased 
several fold with longer PI treatment (Friis-Møller et al, 2007). The question this poses is, how can 
this drug lead to something as severe as CVD? Even though the underlying causes remain unclear, 
we have developed, with support from literature from the literature, some theories. 
Our first theory is that the PIs, or its metabolites, directly affect specific tissue types by direct binding 
to heart cells or nuclei and thereby activating harmful pathways. Such pathways are then proposed 
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to cause decreased functioning or apoptosis, thereby leading to specific symptoms presenting in 
HIV-positive patients receiving ART. This theory is strengthened by work done on murine models 
that suggest the possibility of direct cellular mechanisms through which PI treatment might promote 
atherosclerosis (Jiang et al, 2006; Jiang et al, 2007, Wang et al, 2007). 
 
In addition Hong-Brown and colleagues (2008) showed that in vitro PI treatment can lead to the 
activation of 5' adenosine monophosphate-activated protein kinase (AMPK) through direct effects 
on AMPK downstream regulators (Hong-Brown et al, 2008). AMPK is an important cellular regulatory 
protein, involved in various pathways. It is catabolic by nature, allowing for increased energy 
availability. Activation of AMPK can thus lead to decreased protein synthesis (Hong-Brown et al, 
2008). It is thus not farfetched to speculate that HIV PIs, or their metabolites, could potentially have 
direct effects on cells, tissues and their functioning through this and/or other pathways. 
 
Our second theory is that the PIs (or its metabolites) lead to type-2 diabetes. It is commonly 
observed that patients on PI treatment develop altered blood profiles, presenting with 
hyperlipidemia, hypercholesterolemia and hyperglycemia (Carr, 2000; Stein, 2001; Tsiodras et al, 
2000). How these metabolic disturbances occur is not known, but the above-mentioned symptoms 
are also common during the development of type 2 diabetes (Sivitz and Yorek, 2010). Type-2 
diabetes is known to cause some severe health problems of its own if left untreated, e.g. kidney 
failure, blindness and of particular concern, CVD (Sivitz and Yorek, 2010).  
 
Figure 1.3. This graph depicts the adjusted relative rates of myocardial infarction according to the 
according to the cumulative exposure to PIs and NNRTIs. The estimates were based on Poisson 
regression models. The multivariable model was adjusted for sex, cohort, HIV transmission group, 
race or ethnic group, age, body-mass index, family history of cardiovascular diseases, smoking 
status, previous cardiovascular event, and calendar year (Friis-Møller et al., 2007). 
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Diabetes is also a known cause of mitochondrial dysfunction, which has been a suspected cause of 
some of the clinical symptoms. We therefore postulate that the PI treatment could cause type 2-
diabetes through alterations in the blood profile, which eventually leads to mitochondrial 
dysfunction and heart disease. Thus the PI treatment does not directly cause CVD, but the latter is a 
secondary effect. 
 
Our third and final theory is that PI treatment directly leads to mitochondrial dysfunction. In 
support, other studies also theorised that PIs or its metabolites may potentially affect mitochondria 
in a direct fashion (Phenix, 2001; White, 2001). We believe that such interaction(s) could affect 
mitochondrial function and energy production, for eg.  directly binding or inhibiting electron 
transport chain (ETC) complexes. Mitochondrial dysfunction would subsequently lead to decreased 
energy production and increased reactive oxygen species (ROS) production potentially causing cell 
death. The findings by Hong-Brown and colleagues (2008) that PI activate AMPK in vitro strengthen 
this theory (Hong-Brown et al, 2008). If energy production by mitochondria are diminished the cells 
would respond by activating AMPK. The activation of AMPK would serve to increase energy 
production, but this will be discussed in detail at a later stage. 
 
It is possible that the PIs directly affect the mitochondria by another means. It could be by adversely 
affecting metabolism of different substrates involved in mitochondrial energy production. 
Alterations of glucose and fatty acid metabolism, for instance, is believed to lead to an accumulation 
of such substrates in cells and  possibly even within the circulation, leading to the presentation of 
the symptoms mentioned in the second theory. Eventually type-2 diabetes may develop as a 
secondary effect, which in turn can initiate cardiovascular complications that are often seen in these 
patients (Caballero, 2003; Sivitz and Yorek, 2010; Paneni, 2014).   
 
To summarize our final theory we postulate that the PIs cause direct effects on mitochondria or their 
metabolism that lead to the eventual progression to diabetes, and ultimately CVD. This third and 
final theory that PIs directly leads to mitochondrial dysfunction has provided the platform for this 
study, and will be discussed in more detail from here on. 
 
 1.1.11. Mitochondria: suppliers of life-sustaining energy and detrimental ROS 
 
Mitochondria function as the power stations of cells. Mitochondria are vital in a variety of cellular 
processes, with their primary function the production of adenosine triphosphate (ATP) by aerobic 
respiration (Slater, 2003). However, mitochondria have many other important cellular functions - 
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this will not be discussed at this time. For certain tissues that are continuously active (e.g. the heart 
and brain) ATP production is especially important (Ballinger, 2005). In these tissues mitochondria 
provide energy required for optimal functioning. If ATP production becomes impaired then the 
outcome is often pathological (Finsterer, 2004) – often referred to as ‘’mitochondrial dysfunction’’ 
(Sivitz and Yorek, 2010). 
 
There are a number of reasons why mitochondrial function may become impaired. Firstly, it may be 
due to mitochondrial enzymes that are less effective - due to decreased activity (Vondra et al, 1977; 
Finsterer, 2004). Although such enzymes technically do not affect mitochondria directly, they are 
vital for the normal process of respiration. Mitochondrial enzymes are often responsible for the 
splicing or priming of substrates for mitochondrial utilization. For example, medium-chain acyl-
coenzyme A dehydrogenase (MCAD) and long-chain acyl-coenzyme A dehydrogenase (LCAD) (Wang 
et al,1999; Zhang et al, 2007; Angelini et al, 2011) form part of the oxidoreductases family, and  
function to break down medium and long-chain fatty acids into acetyl-CoA, which can then be used 
in the Krebs cycle for the generation of the reducing agents, NADH and FADH2 (Wang et al,1999; 
White, 2001; Zhang et al, 2007, Sivitz and Yorek, 2010).   
 
The reducing agents, NADH and FADH2 are then used to produce ATP through the ETC which is 
located within the inner mitochondrial membrane. Inhibition of enzymes like LCAD can therefore 
lead to mitochondrial dysfunction since fatty acids such as palmitoyl-carnitine can accumulate and 
directly affect ETC efficiency (Bremer and Wojtczak, 1972; Bremer, 2001; Divakaruni et al, 2012).  
The accumulation of fatty acids, as described, would adversely affect energy production and hence 
cellular function. The ETC is an extremely complex system which will not be discussed in full detail, 
i.e. only details necessary for the understanding of the research question and study design of this 
project will be discussed.  
 
1.1.12. The importance and functioning of the electron transport chain 
 
The ETC is comprised of four protein-complexes spanning the inner-membrane of mitochondria 
(explained shortly) (White, 2001; Sivitz and Yorek, 2010). Mitochondria then utilize such complexes 
to generate energy as electrons are passed from donors at lower redox potentials, to acceptors at 
higher redox potentials (Sivitz and Yorek, 2010).  In parallel, protons are pumped from the matrix to 
the inter-membrane space, leading to a potential difference across the inner-membrane (Scheffler, 
1999).  
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The potential difference that is generated is then used to generate ATP through a fifth protein-
complex spanning the inner-membrane known - ATP synthase [F0̇F1ATPase] (Arechaga et al, 2001). A 
small portion of the proton gradient is dissipated in the form of heat as protons leak back into the 
matrix (Sivitz and Yorek, 2010). The majority of the electrons from the ETC eventually get transferred 
to oxygen, forming H2O  the well known by-product of respiration. A small amount of electrons do 
however leak during transport, leading to mitochondrial superoxide production, which also gives rise 
to additional free radical species (Sivitz and Yorek, 2010).  
 
Although such ROS particles may have serious detrimental effects on cells, a small amount is 
necessary for normal cellular functioning (Finkel and Holbrook, 2000). ROS are important metabolic 
regulators, and can function as mitochondrial uncouplers as well as cellular signaling molecules 
(Dinakar et al, 2010, Ralph et al, 2010).  However, when ROS are produced in higher amounts than is 
required for normal functioning it can trigger detrimental effects (Sivitz and Yorek, 2010). Such an 
excess of free radicals can wreak havoc, leading to the destruction of all biological molecules, 
including DNA, proteins and lipids (Finkel and Holbrook, 2000).  
 
Cells possess antioxidant systems to help counter the above mentioned detrimental effects. These 
include systems such as superoxide dismutases (SOD) and NADPH Oxidase (NOX) (Förstermann, 
2010; Buettner, 2011). Upregulation of systems like SOD and NOX can result in an adaptive response 
when needed; however with continuously high ROS production it cannot sustain its protective 
function and cellular damage occurs.  
Figure 1.4. This figure depicts a simplified portrayal of the electron transport chain. It shows how reducing 
equivalents like NADH can enter the ETC through complex I, while FADH2 enters through complex II. From here 
electrons are passed on to an intermediate ubiquinone, after which it is passed to complex III, whilst protons 
are moved across the inner-membrane of the mitochondrion, to produce a proton gradient. From complex III 
electrons are donated to intermediate cytochrome C, and passed on to complex IV, whilst more protons are 
moved across the membrane. Electrons are finally passed from complex IV to oxygen, to form metabolic water. 
The proton gradient that is produced through the movement of electrons is used to produce ATP though 
ATPase. It can however also be dispersed without production of ATP, through the uncoupling proteins (UCPs). 




In severe cases the damage results in irrepairable intracellular damage and cells can subsequently 
iniate apoptosis through pathways regulated by mitochondria (Green and Reed, 1998; Regula, 2003). 
It should be noted that the regulation of cell death is another key function of mitochondria (Green 
and Reed, 1998).  It is therefore important that cells maintain ‘’safe’’ ROS levels, since excess levels 
can lead to cell death, and in certain tissues (e.g. heart and brain) this can be seriously detrimental, if 
not lethal. 
 
Under normal circumstances the reducing agents, NADH and FADH2 enter the ETC through complex I 
(NADH ubiquinone reductase) and complex II (succinate dehydrogenase), respectively (Slater, 2003; 
Sivitz and Yorek, 2010). As highlighted  in Figure 4, electrons are then transferred from the entry 
sites to complex III (ubiquinol-cytochrome c reductase) through a mobile intermediate ubiquinone 
(Scheffler, 1999; Slater, 2003).  
 
At complex III ubiquinol becomes oxidized and electrons are transferred to another mobile 
intermediate known as cytochrome C (Slater, 2003). The electrons are then carried to complex IV 
(cytochrome C reductase), where cytochrome C becomes oxidized and electrons are passed to O2, 
which leads to the production of metabolic H2O (Scheffler, 1999). The proton gradient (membrane 
potential) is created by H+ ions that are continously translocated to the intermembrane space 
through complex I, III and IV (Fig. 3). As mentioned previously, this proton gradient is then used to 
drive ATP production through complex V (ATPase).  
 
1.1.13. Mitochondrial proton gradient not only used for energy production 
 
Under certain circumstances the proton gradient is not coupled to ATP production (Nicholls, 2001). 
These circumstances were the proton gradient does not produce ATP occurs due to another class of 
protein complex known as uncoupling proteins (UCPs). UCPs span the mitochondrial membrane and 
cause electrons to leak back into the mitochondrial matrix without the production of ATP (Fig. 3) 
(Nicholls, 2001). Superoxide can activate UCPs, leading to less ATP  formed per reducing agent (Fink 
et al, 2007).  This process may appear as a  detrimental effect but occurs under normal homeostatic 
conditions. For example, a well-known scenario is post-prandial heat production (Clarke et al, 2012), 
i.e. heat generation by mitochondrial UCPs explains why individuals feel warm after consuming a 
meal.  Additionally, the heat generated by UCPs is vital for maintaining our constant body 
tempratures. 
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A more serious scenario occurs when one or more of the ETC complexes are inhibited. For example, 
compounds such as the toxin, cyanide, can inhibit complex IV (Zhang et al, 1990)  and electrons 
transferred to O2, inhibiting futher flow of electrons through the ETC. This then causes dissipation of  
the proton gradient through UCPs with no further ATP formation. In addition to the inhibition of 
complex IV, superoxide is still produced by coplexes I and III that further activates UCPs as 
mentioned before (Stivitz and Yorek, 2010).   
Low doses of other types of compounds (e.g. fucoxanthin and caffeine) can also lead to uncoupling 
of mitochondria, but not to the extent that is fatal.  It can instead increase superoxide production 
with mild UCP activation (Kogure et al, 2002; Maeda et al, 2005; Pang et al, 2008), resembling that of 
the post-prandial scenario.  In light of these discussions, it seems plausible that PI treatment could 
potentially lead to mitochondrial uncoupling, causing decreased ETC efficiency, altered ATP 
production and increased ROS production.   
 
 1.1.14. Mitochondrial morphology affects respiratory capacity 
 
Mitochondrial dysfunction may also be attributed to the morphology of these organelles (Sivitz and 
Yorek, 2010). Mitochondria are double-membraned, with the inner-membrane folded (cristae) 
extensively. Such  folding lead to a dramatic increase of  the mitochondrial surface area (Sivitz and 
Yorek, 2010). Since the ETC is situated in the inner-membrane, it is beneficial for its surface area to 
be as large as possible in order to house numerous ETC complexes.   
 
Mitochondrial morphology can be dramatically altered with certain disease states. For example, 
type-2 diabetes is a well-known cause of mitochondrial dysfunction (Heilbronn et al, 2007; Ritov et 
al, 2010; Sivitz and Yorek, 2010) and can elicit morphological changes (e.g. enlarged with cristae 
almost absent) (Kelley et al, 2002).  The altered mitochondrial morphology results in a decrease in 
surface area which in turn adversly affects aerobic metabolism. These effects on respiratory capacity 
is interesting since the prevelance of type-2 diabetes among patients receiving PI-treatment is 
relatively high (Capeau et al, 2012).  The increased prevelance of type-2 diabetes among PI-treated 
individuals raises the question of whether mitochondrial dysfunction observed in such instances is 
causitive or symptomatic of the diabetes.  These findings forms part of ongoing research endeavors 
world-wide. 
 
1.1.15. Decreases in mitochondrial number also implicated in type-2 diabetes 
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Mitochondrial number is another determining factor in metabolism, e.g. lower numbers result in 
slower aerobic metabolism. There are two distinct populations of mitochondria in muscle tissue. The 
distinction between the two populations is based on their subcellular localization, but they also 
differ with regards to size, morphology and enzyme activities. These two populations are known as 
sub-sarcolemmal mitochondria (SSM) and intermyofibrillar mitochondria (IFM). The SSM are located 
just underneath the sarcolemma and have a large lamellar shape. The IFM are smaller in size, and 
located in between the contractile units.  
Type-2 diabetes is implicated with decreased mitochondrial numbers, especially the sub-
sarcolemmal (SSM) population (Kelley et al, 2002; Morino, et al, 2005; Ritov et al, 2005). Together 
with morphological and ETC alterations, this leads to metabolism being severely affected. Once 
mitochondria are damaged or display altered morphology, they are removed by a process known as 
autophagy. The process of removal occurs because damaged mitochondria (e.g. due to increased 
ROS) often leads to cell death signaling, and is therefore a preventative mechanism (Kim et al, 2007). 
The process of removing mitochondria through autophagy is termed mitophagy. However, in some 
instances mitophagy can be  inhibited thereby leading to  damaged mitochondria continuously 
producing ROS. The exact mechanism of such  down-regulation is unclear (Kim et al, 2007). 
Nevertheless, mitochondrial number and efficacy is important for maintaining adequate metabolism 
and sustaining life. 
 
1.1.16. Modulators involved in regulation of mitochondria and metabolism 
 
Mitochondrial biogenesis have been found to be down-regulated in individuals with type-2 diabetes 
(Morino et al, 2005). Thus individuals suffering from type-2 diabetes can exhibit lower mitochondrial 
numbers and some degree of dysfunction. The exact mechanisms of such dysfunction are not 
known, but the answer may lie with regulators of mitochondrial biogenesis (Sivitz and Yorek, 2010).  
The three most important regulators are: AMPK, silent mating type information regulation 2 
homolog 1 (SIRT-1), and peroxisome proliferator-activated receptor gamma coactivator 1-alpha 
(PGC-1α).  It is proposed that altered expression of such regulators are implicated in mitochondrial 
dysfunction (Sivitz and Yorek, 2010). 
 
Such regulators can be activated or upregulated in different ways.  However,  once activated, they 
work synergistically to increase metabolism (Cantό et al, 2009; Ruderman et al, 2013). One way of 
achieving increased metabolism is by increasing mitochondrial biogenesis (Zong et al, 2002; Hardie 
et al, 2007). Mitochondrial biogenesis leads to increased mitochondrial numbers which in turn 
increases energy production. Secondly the regulators increase metabolism by increasing the number 
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of ETC complexes and ETC efficiency (Cantό et al, 2009). And lastly, the regulators cause increased 
metabolism through increased substrate availabilty and subsequent increases in metabolic flux 
(Cantό et al, 2009). 
 
The regulators highlighted respond to a number of stimuli, e.g.  insufficient intracellular ATP levels 
(Cantό et al, 2009; Zhang and Wu, 2009). When the ADP/ATP ratio increases, the cell senses an 
energy shortage which leads to activation of AMPK. The activation of AMPK increases metabolism 
and substrate utilization with the goal of producing more ATP. The increased ATP production by 
AMPK is achieved by increases in fatty acid uptake and oxidation, increased glycogen breakdown, 
increased gluconeogenesis, enhanced glucose uptake, upregulated ETC complex production, and a 
general increase in mitogenesis (Ruderman et al, 2013). In addition AMPK activation also leads to the 
stimulation of SIRT-1 and PGC-1α. The importance of these two regulators will be explained in the 
following pages. It is important to note that AMPK activation has many other effects that are not the 
focus of this study. 
 
These two regulators further increase mitochondrial numbers (Cantό et al, 2009; Ruderman et al, 
2013). Together these effects can result in increased mitochondrial ATP production.. 
 
1.1.17. HIV and HAART can affect both regulators and flux of metabolism 
 
Focusing on HIV-infected individuals (ARV-naïve), it has been discovered that cellular AMPK is down-
regulated and thought to occur through the direct inhibition of SIRT-1 (Mankouri and Harris, 2011).  
This would be expected to elicit negative outcomes on the host’s metabolism. This inhibition of SIRT-
1 is though to occur as a result of circulating HIV proteins e.g. TAT and GP120, both implicated in 
cardiotoxic effects of the virus itself (mentioned previously). Certain ARTs can trigger similar effects 
on the ETC, especially NRTIs (White, 2001) and this may occur due to a strong decrease in 
mitochondrial DNA.  Here NRTIs are incorporated into the host DNA thereby preventing its 
replication (White, 2001).  It therefore stands to reason that individuals suffering from HIV/AIDS and 
receiving ART, have increased chances of suffering from metabolic distrurbances. 
 
The regulator, SIRT-1, primarily comes into play during times of fasting/starvation. SIRT-1 is part of 
the sirtuin family, a group of deacetylases that regulate nutrient usage (Cantό et al, 2009). The 
sirtuins achieve this through their ability to modify gene expression as well as target histones, 
metabolic transcription factors and co-regulators, of importance in our setting is AMPK and PGC-1α 
Stellenbosch University  https://scholar.sun.ac.za
33 
 
(Amat et al, 2009; Chung et al, 2012). During fasting/starvation the body does not receive adequate 
calories through the diet, so alternative sources needs to be accessed (Chung et al, 2012).  
 
The decreased energy production due to fasting/starvation is sensed on a cellular level due to an 
increase in the NAD+/NADH ratio (Cantό et al, 2009; Chung et al, 2012). SIRT-1 is up-regulated to 
correct this problem before the organism is detrimentaly affected. As previously mentioned, 
activation of SIRT-1 leads to the co-activation of AMPK and PGC-1α (Fullerton and Steinberg, 2010). 
These can then act in synchrony to increase availabilty of substrates for energy production. AMPK is 
catabolic, leading to the breakdown of all types of macromolecules in storage namely; protein, fat 
and carbohydrate. Thus supplying substrates for ATP production from sources stored in the body for 
exactly these scenarios. HIV has however been implicated in decreasing SIRT-1 and hence affecting 
metabolism (Zang and Wu, 2009). 
 
PGC-1α on the other hand,  is a co-activator which serves as another master regulator of genes 
involved in metabolism (Mendelsohn and Larrick, 2011). It is thought to be the down-stream 
mediator of AMPK and SIRT-1 (Fullerton and Steinberg, 2010; Mendelsohn and Larrick, 2011). Its 
activity exerts different effects on metabolism in different tissues. In brown addipose tissue for 
example, it increases UCP1 expression and genes involved in mitochondrial oxidative pathways. In 
the liver PGC-1α is responsible for inducing genes involved in gluconeogenesis. In skeletal muscle it is 
capable of increasing metabolic flux in response to exercise (Fullerton and Steinberg, 2010).  
 
PGC-1α  is especially sensitive to acetylation/activation by SIRT-1 (Liang and Ward, 2006). 
Eventhough it has a range of effects in various tissues, all the effects are linked to increasing 
metabolism or efficacy thereof. As mentioned before HIV is suspected to lead to decreased activity 
of AMPK through the viral inhibition of SIRT-1 (Zhang and Wu, 2009). Thus implying that HIV might 
negatively affect PGC-1α levels and activity as well. Given the major role that PGC-1α plays in 
metabolism any alterations to its functioning could be detrimental to the organism, in our setting 
the HIV-positive patient receiving PIs. 
 
Taken together, the three regulators of metabolism act in unison to; increase substrate availability, 
increase metabolic flux and efficacy, and ultimately increased energy production. These three 
regulators are all interlinked and if one is to be down-regulated it affects the other two (Canto et al, 
2009). This would have undesirable effects on mitochondria and ultimately decrease energy 
production. As previously mentioned, it has been observed in certain studies that these regulators 
and subsequent metabolism can be negatively affected by certain compounds or viruses (Cant et al, 
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2009; Chung et al, 2012). It thus seems plausible to propose that PI treatment could have similar 
effects on one or more of these regulators. 
 
It is important to note that there is another regulator of metabolism that has not been mentioned. It 
is known as thyroid hormone, and makes up part of the hypothalamic-pituitary-adrenal axis. This 
hormonal system controls reactions to stress and regulates many bodily processes (Bhangoo and 
Desai, 2013). Certainly one of the most important functions, with regards to this study, is energy 
storage and expenditure. Thyroid hormone can bind directly to the inner membrane of mitochondria 
and cause an increase in metabolic flux, mitochondrial oxygen consumption and ATP production 
(Meena et al, 2013).  
 
Dysfunction or depletion of thyroid hormone can lead to serious metabolic abnormalities, for 
example hypothyroidism. In this disorder metabolism is impaired due to lowered levels of thyroid 
hormone (Mullur et al, 2014). Hypothyroidism causes patients to be chronically fatigued and gain 
weight (Carvalho et al, 2013; Mullur et al, 2014). In children this disorder can lead to developmental 
problems and cognative impairment (Mullur et al, 2014). Clinically it has been observed that HIV and 
HAART treatment can affect thyroid hormone levels (Desforges et al, 1992; Bhangoo and Desai, 
2013). The clinical presentation thereof does however vary dramatically, ranging from hypo- to 
hyperthyroidism, implying that there are various factors involved (Bhangoo and Desai, 2013).  
 
The prevelance of hypothyroidism has however been found to be higher than that of 
hyperthyroidism (Bhangoo and Desai, 2013; Carvalho et al, 2013; Meena et al, 2013). The higher 
prevelance of hypothyroidism is of significance because it can contribute to the already diminished 
metabolic capacity of HIV-positive HAART treated individuals, worsening quality of life and clinical 
outcomes. 
1.1.18 PIs: where do we go from here? 
 
From the literature it is clear that the introduction of ARVs gave hope to patients infected with HIV. 
It significantly increased life expectancy and quality of life. However it became evident that some 
ARVs do have some detrimental side-effects. Some of these side-effects are so severe that it might 
cause patients to stop treatment. One important class of ARVs, PIs, has been known to cause some 
detrimental side-effects. As previously mentioned the mechanisms involved in these side-effects are 
not well understood. 
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With the brief background given on mitochondrial function it becomes evident that these organelles 
are likely candidates in the development of these side-effects. Further research is needed to identify 
whether the mitochondria are directly affected by the PIs or rather as result of type-2 diabetes and 
altered metabolism. Given PIs undeniable benefit to patients when used as part of combination 
therapy, gaining more insight into the mechanisms behind its side-effects could enable us to 





In light of this, we postulate that sole PI treatment in rodent experimental model would provide a 
unique opportunity to elucidate mechanisms underlying PI-mediated side-effects. We therefore 
hypothesize that PI treatment leads to direct detrimental effects on mitochondrial function.  
Furthermore, we propose that such detrimental effects lead to the presentation of metabolic 
dysfunction (e.g. hyperlipidemia, hypercholesterolemia, diabetes) and the eventual onset of CVD as 
secondary effect.  Finally we postulate that various co-treatments with well-known drug therapies 




 To determine whether PI treatment results in direct detrimental effects on cardiac function. 
 
 To assess whether PI treatments lead to alterations in blood profile and body composition. 
 
 To evaluate whether PI treatment alters mitochondrial respiratory function.  
 
 To assess whether duration of PI treatment affects any aforementioned aims. 
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1.2. Materials and methods 
 
1.2.1. Animal housing 
 
All animals were treated in accordance with the Guide for the Care and Use of Laboratory Animals of 
the National Academy of Sciences (NIH publication No. 85–23, revised 1996) and performed with the 
approval of the Animal Ethics Committee of Stellenbosch University (South Africa). Male Wistar rats 
were acquired at 150-180g body weight. Animals were randomly divided into 6 experimental groups 
consisting of 6 animals each. Animals were housed in standard-sized IVC rat cages (3 animals per 
cage), subjected to 12:12 h light-dark cycles with ad libitum food and water. Rats were fed standard 
rat chow. Animals were weighed every third day to assess weight gain and food was weighed daily. A 
week acclimatization period was permitted to allow animals to get used to handling, as well as 
acquiring the taste for the jelly and method of feeding. 
 
1.2.2. Dosages and treatment preparation: 
 
Experimental groups were as follows: Control, Jelly control, protease inhibitor (PI). Treatment 
dosages were calculated using body surface area (BSA) based on the following formula (Reagan-
Shaw, S. 2008):  
𝑯𝒖𝒎𝒂𝒏 𝑬𝒒𝒖𝒊𝒗𝒂𝒍𝒆𝒏𝒕 𝑫𝒐𝒔𝒆 (
𝑚𝑔
𝑘𝑔
) = 𝐴𝑛𝑖𝑚𝑎𝑙 𝑑𝑜𝑠𝑒 (
𝑚𝑔
𝑘𝑔





Table 1.1. Conversion of human equivalent dose (HED) to animal doses based on BSA 
Species Weight BSA (m2) Km factor 
Human    
         Adult      60 1.6 37 
         Child      20 0.8 25 
Baboon      12 0.6 20 
Dog       10 0.5 20 
Monkey  3 0.24 12 
Rabbit  1.8 0.15 12 
Guinea pig  0.4 0.05 8 
Rat  0.15 0.025 6 
Hamster  0.08 0.02 5 
Mouse 0.02 0.007 3 
Values based on data from FDA Draft Guidelines (Centre for Drug Evaluation and Research, Centre for Biologics 
Evaluation and Research. (2002)Estimating the safe starting dose in clinical trials for therapeutics in adult 
healthy volunteers, U.S. Food and Drug Administration, Rockville, Maryland, USA). 
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The HIV PI, trade name Alluvia™ (purchased from Neelsie pharmacy, Stellenbosch), containing 
200mg Lopinavir/50mg Ritonavir per tablet, was used for the purposes of this experiment. For 
treatment purposes, all pills and capsules were first de-capsulated or de-filmed, crushed with mortar 
and pestle and weighed accordingly. Treatments were prepared and weighed out daily using a 
microscale (Shimadzu AW220) and appropriate weighing boats. 
Raspberry flavoured gelatine (Tower Jelly) was combined with pure gelatine (Sheridans) in a ratio of 
4:1. This ratio was determined during the optimisation period. Jelly blocks were prepared as follows: 
flavoured gelatine and pure gelatine were mixed in a predetermined amount of boiling tap water, 
and stirred until dissolved completely. Jelly solution was then directly pippeted into ice trays with 
volumes ranging from 1.5-2.5 ml, depending on the weights of the rats. Treatments were added to 
each ‘well’ of the ice tray once the jelly solution had cooled. Ice trays were placed in the fridge at 4 
°C until set. 
Treatments were administered daily between 16:00 – 18:00, which coincided with the start of the 
dark cycle. Jelly blocks were fed to rats individually in the same order, up until the day of culling. 
 
1.2.3. Treatment periods and data collection: 
 
Treatments were administered for 2, 4 and 6 months, and various parameters were analysed at the 
end of each treatment period: 
 
  1.2.3.1. Blood collection 
 
Blood was collected at the end of 2 and 4 months of treatment. Rats were sedated using 2% 
isoflurane in oxygen. Adequacy of anaesthesia was monitored by lack of reflex response to a 
foot pinch, after which a total of 1 ml of blood was drawn from each rat’s jugular vein with a 1 
ml syringe and 18 gauge needles. Blood was then transferred into serum tubes (Lasec, 454098), 
and centrifuged at 2000 rpm at 4 °C for 20 min. After centrifugation, the plasma supernatant 
was aspirated and transferred into 500 µl Eppendorf tubes, and sent to the National Health 
Laboratory Services (NHLS – Tygerberg, Western Cape, South Africa) for analysis.  Plasma levels 
of cholesterol, triglycerides and free fatty acids were analysed. 
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  1.2.3.2. Echocardiography 
 
Echocardiography was conducted at the end of 2 and 4 months of treatment. Rats were sedated 
as mentioned above, after which the fur on the chest was shaven. Data was recorded from the 
parasternal short-axis of the rat heart. The following parameters were measured and recorded 
for each rat: Left Ventricular End-Diastolic Diameter (LVEDV), Left Ventricular End-Systolic 
Diameter (LVESD), Left Ventricular End-Systolic Posterior Wall Thickness (LVESPWT), Left 
Ventricular End-Diastolic Posterior Wall Thickness (LVEDPWT) and the R-R interval. Fractional 
shortening was calculated as: (end-diastolic diameter – end-systolic diameter)/end-diastolic 
diameter. 
 
  1.2.3.3. Mitochondrial respiration 
 
Mitochondrial respiration was measured using a DW1/AD oxygen electrode unit (Hansatech). 
The Oxygraph Plus System™ was used to record and analyse results (for buffer components, 
please refer to Appendix A). 
 
  1.2.3.4. Oxygraph assembly and calibration 
 
Two hours before the culling of the rat, the water bath connected to the water jacket 
surrounding the oxygen electrode was turned on and set at 37 °C. All components of the 
oxygraph were thoroughly rinsed and cleaned with distilled water (dH2O), and the metal 
elements of the electrodes were polished. The electrode dome was then covered with an 
oxygen permeable polytetrafluoroethylene (PTFE) membrane and the oxygraph chamber 
was then assembled. Respiration buffer (1.5 ml) was then pippeted into the chamber, and 
allowed to equilibrate at 37 °C for an hour. During this hour, all the necessary buffers were 
prepared. 
 In order to calibrate the oxygraph, a series of on-screen prompts were followed, requiring 
maximum (100%) and minimum (0%) oxygen levels. Maximum oxygen levels were achieved 
by air-saturation (vigorously shaking a tube containing respiration buffer before addition to 
the chamber), and to achieve minimum levels, 0.01 g sodium dithionate was added directly 
to the chamber. 
 
 
Stellenbosch University  https://scholar.sun.ac.za
39 
 
1.2.3.4.1. Isolation of left ventricular sub-sarcolemmal mitochondria 
 
Using 5% isoflurane as a sedative, rats were culled by exsanguination, after which the hearts 
were quickly removed and transferred into a 10 ml beaker containing ice-cold Buffer A. 
Hearts were trimmed of atria, connective tissue and fat and then washed once with 5ml of 
Buffer A. Left and right ventricles were weighed, after which the right ventricles were placed 
into 10% formal saline for histological analysis. The left ventricles were transferred into a 
different 10 ml beaker on ice, and chopped thoroughly into small pieces with a dissection 
scissor. Five millilitres of Buffer B was used to rinse the chopped heart, where after the 
buffer was discarded. The chopped heart was placed into 15 ml of Buffer B and 
homogenized with a polytron homogenizer (Ultr-Turax, tp 18-10) for three seconds. 
Homogenized hearts were then centrifuged (Eppendorf, 5804) at 580 x g for 7 min. The 
supernatant was then poured through mesh into a new centrifugation tube. The remaining 
pellet was subsequently resuspended in 7.5 ml of buffer B and centrifuged as before. The 
supernatant was then added to the supernatant of the previous step, also through the mesh, 
and then centrifuged once more at 580 x g for 7min to rinse. The remaining supernatant was 
subsequently transferred into a new centrifuge tube for a final centrifugation step at 3000 x 
g for 7 min where it was then discarded and the pellet containing the sub-sarcolemmal 
mitochondria was resuspended in 0.3 ml of KME buffer. 
All of the steps involved were done either on ice, or at 4 °C, this includes centrifugation steps. 
Additionally, the liver, gastrocnemius muscle, retroperitoneal fat pad (RFD), testicular fat pad (TFP) 
and tibia were harvested from each rat for further analysis.  
 
1.2.3.4.2 Mitochondrial oxygen consumption analysis 
 
In order to ensure that an equal quantity of mitochondrial protein was utilized during 
analysis, the Bradford protein quantification method was employed (Bradford, 1976). Two-
hundred-and-fifty micrograms of mitochondrial protein was added to the oxygraph chamber 
containing respiration buffer during each experiment, with a final volume of 1.5 ml, after 
which the stopper was put into place. Different combinations of substrates and inhibitors 
were added to the chamber to elucidate the functioning of different ETC complexes: 
glutamate (20mM) and malate (10mM), malate (10mM) and pyruvate (20mM), malate 
(10mM) and carnitine palmitoyl (40mM), succinate (20mM) and rotenone (7.5mM). 
Between the additions of each substrate combination, the chamber was thoroughly rinsed 
with 70% alcohol and dH2O, after which new mitochondria were added (250 µg). 
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Furthermore, after the addition of each substrate combination, 10mM ADP was added. At 
the point where the graph reached a plateau, an additional 100mM of ADP was added. Once 
the slope of the line graph remained constant, 5mM Oligomycin-A was added in order to 
significantly reduce electron flow through the ETC. Mitochondria from each rat was analysed 
for all of the above mentioned substrate combinations. 
Remaining mitochondria were snap-frozen in liquid N2, and stored at -80 °C for future analysis in a 
cryoprotectant freezing buffer for further. 
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1.3.  Results 
1.3.1 Weight gain analysis 
 
In order to establish the effects PI treatment on body weight and net weight gain, all experimental 
groups were weighed every third day (for 2, 4 and 6 month groups, respectively).  The data revealed 
that all groups gained weight equally over the 2 month treatment period; no significant differences 





Figure 3.1. Body weight and net weight gain in male Wistar rats following 2 months of treatment. A) 
Total body weight during the second month of treatment, n = 24. B) Weight gained over the second month 
of treatment, as calculated from the starting weight, n=24. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with a Bonferroni post-hoc test. PI – protease inhibitor.  
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After 4 months, PI-treated rats displayed decreased body weights compared to controls (*p < 0.05 
vs. control; @@@p < 0.001 vs. Jelly, Fig 3.2.A).  Similarly, net weight gain was decreased (***p < 0.001 
vs. Control; ***p < 0.001 vs. Jelly) compared to controls (Fig. 3.2.B). 
 
Figure 3.2. Body weight and net weight gain in male Wistar rats after 4 months of treatment. A) Total body 
weight over the fourth month of treatment: *p < 0.05 vs. control, @@@p < 0.001 vs. jelly, n = 12. B) Weight 
gained over the fourth month of treatment, as calculated from the starting weight: ***p < 0.001 vs. control, 
@@@p < 0.001 vs. jelly n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with a 
Bonferroni post-hoc test. PI - protease inhibitor.  
 
 




This pattern changed with prolonged treatment, i.e. 6 months PI treatment resulted in increased 
total body weight and net weight gain (**p < 0.01 vs. Jelly and ***p < 0.001 vs. Control) when 






Figure 3.3.  Body weight and net weight gain in male Wistar rats after 6 months of treatment. A) Total body 
weight over sixth month of treatmen: ***p < 0.01 vs. control, **p < 0.01 vs. control, n = 6. B) Weight gained 
over sixth month of treatment, as calculated from the starting weight, ***p < 0.01 vs. control, **p < 0.01 vs. 
control, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with a Bonferroni post-
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1.3.2 Analysis of triglyceride, cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) blood levels 
 
In order to establish the effects of treatments on various markers that are commonly related to 
metabolic disturbances, blood samples were collected at the end of 2 and 4 months of treatment, 
respectively, for metabolite analysis.   No changes were observed in any of the blood parameters 
























Figure 3.4. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 2 months of 
treatment. A) No changes were observed in triglyceride levels, n = 6. B) No changes were observed in 
cholesterol levels, n=6. C) No changes were observed in HDL levels, n=6. D) No changes were observed in the 
LDL levels, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni 
post-hoc test. PI - protease inhibitor. 
 






Figure 3.5. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 4 months of treatment. A) 
No changes were observed in triglyceride levels, n=6. B) No changes were observed in total cholesterol, n=6. C) No 
changes were observed in HDL, n=6. D) No changes were observed in LDL levels, n=6. All results expressed as mean 
± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor. 
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 1.3.3 Analysis of mid-wall fractional shortening (MWFS) with the use of 
echocardiography 
 
In order to establish the effects of each treatment on systolic functioning, various functional 
parameters were assessed with echocardiography. These results were used to calculate mid-wall 
fractional shortening at the end of the 2 and 4 month treatment periods.  We were unable to attain 
echocardiographical data at the 6 month time point due to logistical issues.  No significant changes 
were observed in left ventricular functional parameters after 2 and 4 months of PI treatment, 





 Control Jelly PI 
LVEDD 6.0 ± 0.13 6.0 ± 0.09 6.6 ± 0.08 
LVESD 2.9 ± 0.14 3.3 ± 0.14 3.6 ± 0.11 
LVESPWT 1.9 ± 0.05 1.8 ± 0.05 1.9 ± 0.08 
LVEDPWT 2.6 ± 0.07 2.4 ± 0.09 2.6 ± 0.11 







 Control Jelly PI 
LVEDD 6.4 ± 0.13 6.6 ± 0.16 6.4 ± 0.16 
LVESD 3.6 ± 0.12 3.5 ± 0.15 3.8 ± 0.14 
LVESPWT 2.1 ± 0.07 2.0 ± 0.09 1.9 ± 0.04 
LVEDPWT 2.6 ± 0.1 2.6 ± 0.09 2.4 ±  0.09 









Table 3.1.A. Left ventricular parameters as measured with echocardiography after 2 months of PI treatment  
 
Table 3.1.B. Left ventricular parameters as measured with echocardiography after 4 months of PI treatment  
 
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 

















Figure 3.6. MWFS in male Wistar rats after 2 and 4 months of treatment. No significant changes were 
observed, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test. PI - protease inhibitor. 
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1.3.4 Organ harvesting for the determination of treatment-induced anatomical changes 
 
In order to determine whether the treatments induced any gross anatomical changes, body 
weight was determined together with various organ weights - normalized to tibial length.  No 
significant changes were observed after 2 or 4 months of PI treatment (Fig. 3.7.A & B). After 6 
months, PI-treated rats displayed increased heart weight (*p < 0.05 vs. control, @p < 0.05 vs. 



























Figure 3.7. Heart weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 
and 6 months of treatment. 2 months: No significant changes were observed, n=12. 4 months: No significant 
changes were observed, n=12. 6 months:  *p < 0.05 vs. control, n=12. All results expressed as mean ± SEM, 
statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor. 
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Left ventricular weight increased in both Jelly and PI treated groups versus controls after 4 months 
of treatment (*p < 0.05 vs. control, Fig. 3.8A).  In parallel, right ventricular weight decreased in both 
Jelly and PI treated groups after 4 month of treatment (*p < 0.05 vs. control, Fig. 3.8.C).  No changes 































Figure 3.8. Left and right ventricular weights normalized to total heart weight in male Wistar rats 
on the day of culling after 4 and 6 months of treatment, respectively. A) 4 months: *p < 0.05 vs. 
control, n=12. B) 6 months: No significant differences were observed, n=12. All results expressed as 
mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease 
inhibitor.  
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Liver weight normalized to right tibia length remained unchanged for all groups after 2, 4 and 6 
months of treatment (Fig. 3.9). 
  
Figure 3.9. Liver weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 and 6 
months of treatment. 2 months: No significant changes were observed, n=12. 4 months: No significant changes 
were observed, n=12. 6 months:  No significant changes were observed, n=12. All results expressed as mean ± SEM, 
statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor. 
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For fat mass evaluations, no significant changes were observed after 4 months of PI treatment (Fig. 
3.10.A).  However, rats that were fed jelly cubes displayed increased retroperitoneal fat mass 
compared to controls after 6 months (*p < 0.05 vs. Control, Fig. 3.10.B). 
 
  
Figure 3.10. Left and right ventricular weights normalized to heart weight in male Wistar rats on the day of 
culling after 4 and 6 months of treatment. A) 4 months: No significant changes were observed, n=12. B) 6 
months: *p < 0.05 vs. control, n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA 
with Bonferroni post-hoc test. PI - protease inhibitor.  
 
Stellenbosch University  https://scholar.sun.ac.za
52 
 
 1.3.5 Analysis of mitochondrial respiration  
1.3.5.1 State III respiration of isolated sub-sarcolemmal mitochondria after 4 months of 
PI treatment. 
 
Mitochondrial oxygen consumption was assessed using oxygen electrodes (oxygraph) in sub-
sarcolemmal mitochondria isolated from left ventricles after 4 and 6 months of PI treatment, 
respectively.  After the 4 month treatment period, State III respiration was impaired in isolated 
mitochondria of PI-treated rats with glutamate and malate as substrates (p < 0.05 vs. control, Table 
3.2.A). Although State III respiration was diminished with PI treatment, the ADP:O ratio was 
increased (p < 0.05 vs. control, Table 3.2.A).   
 
 
   CONTROL 
 
     JELLY 
 
       PI 
Glutamate + Malate State III    200 ± 12   248 ± 75   150 ± 13* 
Glutamate + Malate State IV      56 ± 12     97 ± 26     64 ± 5 
Glutamate + Malate RCR   2.53 ± 0.28  2.51 ± 0.21  2.37 ± 0.22 
Glutamate + Malate ADP:0     2.0 ± 0.1    2.2 ± 0.4    2.7 ± 0.3* 
      
Malate + Pyruvate State III    151 ± 19   164 ± 19   166 ± 22 
Malate + Pyruvate State IV      67 ± 10      55 ± 4     63 ± 8 
Malate + Pyruvate State RCR     2.4 ± 0.32  2.95 ± 0.2  2.87 ± 0.4 
Malate + Pyruvate State ADP:O   2.78 ± 0.31  2.61 ± 0.30  2.58 ± .029 
      
Palmityl – Carnitine + Malate State III    178 ± 31   303 ± 105   172 ± 17 
Palmityl – Carnitine + Malate State IV      90 ± 4     93 ± 23     83 ± 9 
Palmityl – Carnitine + Malate RCR   1.96 ± 0.3  3.14 ± 0.51    2.2 ± 0.34 
Palmityl – Carnitine + Malate ADP:O   2.50 ± 0.39  1.95 ± 0.44  2.43 ± 0.21 
      
Rotenone + Succinate State III    285 ± 53   287 ± 74   313 ± 71 
Rotenone + Succinate State IV 146.7 ± 43   126 ± 26   193 ± 65 
Rotenone + Succinate RCR   2.41 ± .59  2.29 ± 0.27  2.22 ± 0.78 






Table 3.2. Function of isolated left ventricular sub-sarcolemmal mitochondria after 4 months of PI treatment. 
All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test: * p < 0.05 
vs. control, n=6. PI - protease inhibitor. 
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1.3.5.2 State III respiration of isolated sub-sarcolemmal mitochondria after 6 months of 
PI treatment. 
 
No changes were observed in mitochondrial respiration following 6 months of PI treatment (Table 
3.3).  
  CONTROL      JELLY        PI 
Glutamate + Malate State III  176 ± 10  167 ± 13  161 ± 16 
Glutamate + Malate State IV    45 ± 5    48 ± 7    43 ± 4 
Glutamate + Malate RCR 4.16 ± 0.46   3.7 ± 0.37   3.8 ± 0.28 
Glutamate + Malate ADP:O 2.32 ± 0.13 2.47 ± 0.18 2.61 ± 0.26 
    
Malate + Pyruvate State III  129 ± 24  157 ± 16  193 ± 28 
Malate + Pyruvate State IV    38 ± 2    40 ± 6    49 ± 7 
Malate + Pyruvate State RCR 3.97 ± 0.31 4.14 ± 0.28 3.99 ± 0.13 
Malate + Pyruvate State ADP:O 2.73 ± 0.19 2.66 ± 0.21 2.26 ± 0.28 
    
Palmityl – Carnitine + Malate State III  150 ± 15  156 ± 8  183 ± 8 
Palmityl – Carnitine + Malate State IV    42 ± 6    44 ± 5    51 ± 1 
Palmityl – Carnitine + Malate RCR 3.87 ± 0.52 3.71 ± 0.39 3.61 ± 0.25 
Palmityl – Carnitine + Malate ADP:O 2.78 ± 0.24   2.6 ± .14 2.21 ± 0.1 
    
Rotenone + Succinate State III  209 ± 47  285 ± 10  201 ± 65 
Rotenone + Succinate State IV    51 ± 16    74 ± 4    51 ± 17 
Rotenone + Succinate RCR 5.03 ± 1.1 3.93 ± 0.28   4.0 ± 0.33 















Table 3.3. Function of isolated left ventricular sub-sarcolemmal mitochondria after 6 months of PI treatment. 
All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test.  PI - 
protease inhibitor, n=6. 
 





HIV is a major disease burden in South Africa and globally as well. It dramatically decreased quality 
of life (QOL) (Whoqol Hiv Group, 2004; Mannheimer et al, 2005) and is the leading cause of death in 
South Africa (Bradshaw et al, 2012). The introduction of HAART has not only slowed disease 
progression but also significantly increased QOL (Mannheimer et al, 2005). However, HAART can 
elicit side-effects that can threaten the well-being of treated patients and these include renal failure, 
hepatic steatosis, diabetes and CVD (Friis-Møller, 2010; Gupta et al, 2013).  
 
The HIV protease inhibitors have especially been implicated in the risk of developing cardiovascular 
complications (Friis-Møller et al, 2007; Friis-Møller, 2010).  For example, Friis-Møller and colleagues 
also observed a correlation between duration of protease inhibitor treatment and increased risk of 
cardiovascular events (Friis-Møller et al, 2007). There are various theories regarding the underlying 
mechanisms whereby protease inhibitors can trigger such side-effects, although compelling evidence 
is still lacking (Zha et al, 2011; Pérez-Matute et al, 2013).   For example, it has been postulated that 
dyslipidemia may be the cause of cardiovascular complications in such individuals (Mallewa et al, 
2008) as increased visceral and central fat have been implicated with risk of developing type-2 
diabetes and CVD (Lafontan, 2013). In this theory, PI treatment leads to development of insulin 
resistance and type-2 diabetes, with CVD occurring only as a secondary treatment-induced effect. 
This concept is strengthened in the literature since insulin resistance and type-2 diabetes is a 
common occurrence in patients on HAART, especially regimens containing PIs (Rudich et al, 2005; 
Noor et al, 2006; Taylor et al, 2010; Capeau et al, 2012).  
 
Others propose that the drug exerts its effects on the cardiovascular system due to mitochondrial 
dysfunction, ROS production, systemic inflammation and cellular apoptosis, leading to direct effects 
in terms of the onset of cardiovascular complications (Pérez-Matute et al, 2013; Reyskens and Essop, 
2013). The schools of thought thus differ where one theory postulates that PI-treatment causes CVD 
directly with diabetes as an additional detrimental side-effect, while the other theory states that 
CVD are secondary due to the development of diabetes caused by the PI treatment.  These theories 
thus cause a chicken-or-egg question; does one come before the other? In light of this, the current 
study was initiated to shed further light on this intriguing question. 
 
The recorded bodyweights followed a surprising trend over the 6 months of treatment. Here after 2 
months of PI treatment neither body weights nor weight gain differed between groups (Fig 3.1), 
while at 4 months however the PI-treated groups displayed the lowest body weight/weight gain (Fig. 
3.2).  However, after 6 months the PI-treated group exhibited the highest recorded body weights 
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and weight gains (Fig. 3.3). It is difficult to explain the initial trends in weight gain but we believe it 
follows the same pattern as clinical studies done by Nell and Essop (unpublished data) on HIV-
positive patients receiving HAART.  Such patients generally showed a period of stable body weight 
and body composition followed by wasting, i.e. a decline in body cell mass, lean body mass, free fat 
mass and peripheral adipose tissue were observed. As treatment continued, the pattern changed 
with body weight increasing along with muscle mass and body cell mass.  This was accompanied by 
significant increases in visceral/central adipose tissue and waist-to-hip ratios, as confirmed in other 
studies (Mallewa et al, 2008; Pérez-Matute et al, 2013).  However, the patients received 
combination ART of which most were on first-line therapy and not receiving PIs.  Lee and colleagues 
(2004) found that HIV-negative men receiving clinical doses of PI monotherapy (ritonavir/lopinavir) 
twice daily for four weeks presented with metabolic disturbances and altered blood profile but no 
changes in body weight, body fat, or abdominal adipose tissue (Lee et al, 2004).     
 
It thus begs the question; how does PI monotherapy in HIV-negative rats (as in our study), present 
with similar trends as that of clinical studies of HIV positive humans receiving HAART but differ from 
results from PI monotherapy in HIV-negative persons?  
 
Firstly, the duration of the PI monotherapy administered by Lee and colleagues (2004) was only for a 
four-week period and this is a relatively short time (clinically speaking), considering that PI-mediated 
side-effects increase in severity with time (Lee et al, 2004; Friis-Møller, 2010).  If treatment duration 
is not the reason for such discrepancies then another possible explanation may be that PI treatment 
of rats may resemble the effects caused by the combination of ART and HIV-infection in humans.   
There is no scientific support for this explanation; however, we postulate that this could occur due 
to side-effects occurring more rapidly in rats possibly due to faster metabolism. For instance, if rat 
mitochondria produce ROS at a much higher rate due to the drug effects then this should lead to 
systemic inflammation similar to that of an advanced-stage HIV-positive ARV-treated individual. In 
support of this idea, Gupta and colleagues (2012) found the manifestation of lipodystrophy, insulin 
resistance, and hyperlipidemia in mice after four weeks of treatment with ritonavir/lopinavir (Gupta 
et al, 2012). This study provides more evidence for the idea that four weeks of PI monotherapy is 
sufficient to induce clinically relevant alterations in body composition and blood profiles in small 
animal models. Such differences once again highlight the difficulty in translation from animal models 
to clinical studies, and vice versa. 
 
To explain possible mechanism behind this pattern of weight gain observed in our study we propose 
changes in adipose tissue distribution to be the most likely cause. Lipodystrophy in HAART-treated 
HIV-positive individuals presents clinically as decreased peripheral adipose tissue and increases in 
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visceral/central adipose tissue (Freitas et al, 2011; Sacre et al, 2011).  Lipodystrophy affects 50% or 
more of ARV treated individuals (Bacchetti et al, 2005) and drug-induced, site-specific lipoatrophy 
likely increases in severity as treatment duration increases (Freitas et al, 2011). Of note, although PI 
treatment is considered a primary causative factor in ARV-induced lipodystrophy there are studies 
that show that NRTIs are also implicated (Pérez-Matute et al, 2013).   The alteration of fat 
distribution can also occur with a decrease in body weight and BMI and in certain cases this is 
attributed to only lipoatrophy occurring (Pérez-Matute et al, 2013). Moreover, certain ARV-treated 
individuals present with lipodystrophy but in the form of decreased general fat mass (both 
peripheral and visceral lipoatrophy) thus lowering body weight significantly. Others present with 
site-specific lipoatrophy (peripheral fat) and lipohypertrophy in other areas (visceral fat) with the net 
result meaning it has little or no impact on BMI (Pérez-Matute et al, 2013). In these cases of 
lipoatrophy in combination with lipohypertrophy BMI is not a reliable tool to assess/predict patient 
health and anthropometrical analysis would thus be a better option in this instance.  
 
With this background in mind, we are of the opinion that lipodystrophy may be a possible and 
reasonable cause for the weight patterns here observed. However, we were unable to weigh fat 
pads/sites after 2 months of treatment as we postulated that this was not sufficient to induce 
significant changes.  For 4 and 6 month treatment groups we could unfortunately not confirm the 
presence or absence of lipodystrophy since analysis of all fat sites was logistically not feasible at the 
time of sacrifice. This was due to the need to isolate mitochondria as rapidly as possible for 
respiration studies.  However, we managed to harvest and weigh the retroperitoneal fat pads at 
both time points.   Although data was not significant, there was a trend in the 4 month group that 
showed PI treatment alone decreased retroperitoneal fat pad mass in comparison to the other 
groups. This correlates with results from Gupta and colleagues (2012) who observed significantly 
lower retroperitoneal fat pad mass in mice treated with ritonavir/lopinavir (Gupta et al, 2012). 
Although we were not able to measure all fat sites we believe that this trend could have mimicked 
clinical findings by Nell and Essop (unpublished data).  Thus the proposal is that 4 months of PI 
treatment may be responsible for the decreased general fat mass thereby matching the wasting 
period of HAART-treated patients. After 6 months the opposite was observed and PI treatment was 
associated with significantly increased body weights and weight gains.   However, retroperitoneal fat 
mass weights at 6 months followed the same trend as after 4 months thus making it difficult to 
explain this finding.  It is also possible that other fat pads/sites could have undergone 
lipohypertrophy and/or ectopic fat deposition to cause increases in body weight and weight gain and 
further studies would be required to test this interesting notion.  
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Alternatively, increased mitochondrial ROS production may also be a possible mechanism of PI-
induced lipodystrophy as such drug treatment can lead to mitochondrial dysfunction (direct or 
indirect) which in turn causes increases in mitochondrial ROS production (Reyskens and Essop, 
2013).    This increase in ROS production could lead to serious cellular damage through oxidation of 
DNA, lipids and proteins, possibly even causing cell death through apoptosis (Pérez-Matute et al, 
2013). Pérez-Matute and colleagues (2013) postulated that this could be a possible cause of 
lipodystrophy induced by PI treatment since peripheral adipose tissue and visceral adipose tissue 
possess differing mitochondrial numbers.  It is proposed that peripheral fat (containing higher 
mitochondrial number) produce more ROS than visceral fat leading to more oxidative stress, 
inflammation, and apoptosis – can lead to decreasing peripheral fat mass (Zha et al, 2011).  In 
support, others found decreased mitochondrial DNA in subcutaneous fat of HIV patients with ARV-
induced peripheral lipoatrophy compared to HIV-positive controls (Shikuma et al, 2001).   Decreased 
mitochondrial DNA may occur due to the effects of ROS on mitochondria or due to direct effects of 
PI treatment on mitochondria. Thus it is possible that ROS lead to damage and subsequent cell death 
of especially peripheral adipose tissue cells.  However, further studies would be required to confirm 
whether this is the case in our experimental model.  
 
Food intake is another important variable to take into account when investigating body weight and 
weight gain. We measured food intake daily but no differences were observed between the groups 
during any of the treatment periods (data not shown). The jelly control group showed significant 
increases in body weight and weight gain (Fig. 3.2 & 3.3). Since there were no significant changes in 
food intake this possibility can be ruled out.  We therefore propose that this could be due to a 
slightly increased daily energy intake due to the caloric content of the jelly and/or due to increases 
in muscle mass because of the additional protein content of the gelatine.  However, the results for 
body weights and weight gains for the other groups are likely to be due to PI treatment since the 
caloric content of jelly is very low per volume. 
 
HIV infection and ART has a strong link to CVD which may (in part) be due to the pro-atherogenic 
lipid profile it encompasses. It is a common occurrence for patients on HAART (especially PI 
regimens) to develop a pro-atherogenic lipid profile (Stein et al, 2001; Badiou et al, 2003).   This 
typically entails decreased HDL together with increased LDL and triglycerides levels (Stein et al, 2001; 
Badiou et al, 2003).  However, for our study we found no changes in blood profiles of rats treated 
with PIs for 4 and 6 months, respectively (Figs. 3.4. & 3.5). This was surprising as it would be 
expected to accompany the increases in body weights here observed.  There are several reasons 
why such changes may not have occurred in our model: a) the HIV infection itself has plays a 
significant role in the development of a pro-atherogenic blood profile, b) the PI steady-state 
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concentration was not high enough to elicit an altered blood profile.  As the rats did not present with 
as pro-atherogenic blood profile we exclude it as an early mediator in direct PI-induced effects on 
the cardiovascular system in our setting.   
 
Since the start of the HAART era, there has been an increased incidence of echocardiographic 
abnormalities and cardiovascular complications observed among HIV patients (Mondy et al, 2011).  
For example, Meng and colleagues (2002) found that PI-containing HAART regimens are associated 
with left ventricular hypertrophy and diastolic dysfunction (Meng et al, 2002).  Moreover, HIV-
positive children receiving HAART exhibited high incidences (18%) of mild ventricular dysfunction 
together with progressive increases in left ventricular weight (Fisher et al, 2005). The exact 
mechanisms of such PI-induced structural and functional abnormalities are elusive, but 
hypertension, vascular inflammation, endothelial dysfunction and cardiotoxicity have been proposed 
as potential mediators (Mondy et al, 2011). For the current study there were no changes in the 
functional parameters of the left ventricles (Table 3.1. A & B) nor did mid-wall fractional shortening 
show any differences between groups (Fig. 3.6).  It remains unclear why no changes occurred in our 
model but we propose that a) the PI dosages may have been too low to cause echocardiographic 
outcomes in rats; b) it may be due to the lack of HIV infection in our experimental system;  c) the 
drug on its own is unable to elicit this response and that a combination with HIV is required; and d) 4 
month treatment duration may not have been sufficient to induce alterations and that the 6 month 
treatment may have been a better choice to perform the analysis, especially as heart weight was 
significantly increased. We were unable to perform these studies due to lack of sufficient animal 
numbers and resources at the time.  
 
Since PI treatment can lead to anatomical disturbances in heart and adipose tissues, we also 
assessed organ weights that were normalized to tibia lengths since body weights fluctuate with 
aging in Wistar rats (Yin et al, 1982). Here PI treatment significantly increased heart weights after 6 
months of treatment and this could be due to the initiation of a hypertrophic response (Fig. 3.7.C). 
Further studies are required to confirm this and whether this occurs due to pressure overload as a 
result of increased body size/obesity.   
 
At 4 months we found a significant decrease in State III respiration with PI treatment together with a 
concomitant increase in the ADP:O ratio (Table 3.2).  However, after 6 months no differences were 
found with PI treatment versus controls (Table 3.3).  Thus these data suggest that at after 4 months 
there is an inhibition of complex I as malate/glutamate provide substrates for the citric acid cycle to 
generate NADH for NADH dehydrogenase (complex I).  However, despite this PI-mediated damaging 
effect the ADP:O ratio was higher suggesting that there are some compensatory mechanisms that 
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are activated to elevate mitochondrial ATP generation.  Further studies are required to investigate 
such possibilities.  We are unclear why this effect was not observed after 6 months and speculate 
that it may have been due to the PI dosage not being high enough and/or physiological adaption to 
long-term PIs availability.  This theory of adaptation is strengthened by findings form Miro and 
colleagues (2004) who found up regulation of mitochondrial genes after ART thereby compensating 
for mitochondrial damage (Miro et al, 2004).  
 
It is visible from these results that PI treatment has undesirable side-effects. Although the trends we 
observed are difficult to interpret and explain, they seem to implicate mitochondria as the mediator 
in our setting. Even though we could not confirm, we believe that adipose tissue is very much 
involved in the processes. It is clear that more research is required to explain the mechanisms 
behind these PI-induced side-effects. To further elucidate the possible mechanisms behind the PI-
induced side-effects we thought it fitting to employ interventions with specific functions to test our 
theories behind PI-induced side-effects. These interventions will be the topic of discussion in the 
chapters to follow. 




2.1. Natural interventions: in search of hope 
 
CVD related to HIV/AIDS generally occur late during disease progression (Friis-Møller et al, 2007; 
Friis-Møller, 2010). The life expectancy of HIV-positive individuals has increased dramatically since 
the introduction of ARVs.  This has increased cardiovascular complications in this population group 
(Friis-Møller, 2010), although it remains unclear whether this is due to the virus and/or ARV 
treatment.  
HIV infection is a known risk factor for CVD onset and this can occur by direct effects of viral proteins 
on the heart and vasculature (Cummings and Badley, 2010; Coopusamy, 2010; Johri et al, 2011).  
Thus the HIV-mediated proatherogenic state further increases CVD risk (Ho and Hsue, 2009; Porter 
and Sutliff, 2012).  However, with initiation of ARV treatment HIV progression is halted and viral load 
lowered (Sierra et al, 2005).  Despite such progress, ARV treatment is linked with cardiovascular 
complications (Friis-Møller et al, 2007; Friis-Møller, 2010).  Here protease inhibitors (PI) and 
nucleoside reverse transcriptase inhibitors (NRTI) have been documented to cause metabolic 
disturbances (Friis-Møller et al, 2007; Friis-Møller, 2010), with PIs posing the greatest threat with 
prolonged treatment (Friis-Møller et al, 2007; Friis-Møller, 2010).  
Although the mechanisms of ARV-induced cardiovascular side-effects are not entirely clear, 
mitochondrial dysfunction has been implicated in this process (Phenix et al, 2001; White, 2001). In 
fact, both HIV itself and ARVs are thought to directly affect these ‘powerplants’ of the cell, thus 
wreaking havoc with intracellular energy production and function (White, 2001). Mitochondrial 
energy production has to be kept in perfect balance since ROS generation is a by-product of this 
process (White, 2001; Hwang et al, 2008).  For example, excess ROS are damaging to cell-
membranes, proteins and DNA structures (Sivitz and Yorek, 2010).  If left unchecked ROS can lead to 
inflammation, cell-death (apoptosis), mutations and dysfunctional proteins - all manifesting in HIV-
positive patients receiving ARV treatments (Sivitz and Yorek, 2010; Porter and Sutliff, 2012). 
The most important regulatory factors of mitochondrial energy production are AMPK, Sirt-1 and 
PGC-1α (Sivitz and Yorek, 2010) that when activated can increase intracellular energy availability 
(Cantó et al, 2009; Ruderman et al, 2013).  It has been clinically observed that AMPK levels are 
decreased in HIV-positive patients in the absence of ARV treatment (Mankouri and Harris, 2011). 
This could  potentially disrupt the functioning of the downstream regulatory factors with adverse 
effects on intracellular metabolism (Cho and Lumeng, 2011). For example, attenuated intracellular 
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metabolism was implicated in cardiovascular complications onset found during latter stages of HIV 
infection (Porter and Sutliff, 2012).  
ARVs have been implicated in the disruption of mitochondrial energy production, e.g. it can decrease 
mitochondrial DNA and disrupt mitochondrial function (Friis-Møller, 2010). In addition, Capeau and 
colleagues (2012) found that patients receiving HAART (containing PIs) displayed significantly higher 
than normal incidences of type-2 diabetes (2012), a known cause of mitochondrial dysfunction 
(Capeau et al, 2012). In support, Kelley et al. (2002) reported that mitochondrial numbers were 
significantly decreased and displayed altered morphology in individuals that were obese or 
diagnosed with type-2 diabetes (Kelley et al, 2002).  
Compunding this bleak picture, lipodystrophy and weight gain are two common side-effects of PI 
treatment (Noor, 2007; Gupta et al, 2012) and both are known risk factors for developing type-2 
diabetes and CVD (Noor, 2007; Capeau et al, 2012).  Thus a rhetorical question emerges, i.e. are PIs 
directly responsible for causing mitochondrial dysfunction and CVD, or can it cause development of 
lipodystrophy and type-2 diabetes that eventually results in CVD onset?  If the mitochondrial-based 
theory is valid this makes it a feasible therapeutic target to limit PI-mediated damaging effects on 
overall health and well-being.   This chapter therefore focused on evaluating natural therapeutic 
compounds that may target the mitochondrion and could then be fairly rapidly translated into the 
clinical setting.   
We focused on Resveratrol (RSV) that is enriched in the skin of red grapes (Edwards et al, 2011) and 
been identified as an activator of SIRT-1 activation (Edwards et al, 2011; Kitada et al, 2011). For 
example, RSV-mediated SIRT-1 activation triggered a protective effect against weight gain and 
metabolic syndrome in rats and mice fed a ‘’Western’’ diet (high fat content) (Baur et al, 2006; Price 
et al, 2012).  Although such promising effects were confirmed in a number of small animal models, 
its therapeutic impact in remains unclear (Poulsen et al, 2012).  In light of this, we proposed RSV 
supplementation together with PI treatment may ameliorate the damaging side-effects usually 
elicited by PIs.    
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2.2. Materials and methods 
 
RSV was purchased in the form of 500 mg capsules (Terraternal, USA). The dosage employed was 
200 mg per kilogram body weight and all analyses/experiment performed were done as described in 
Chapter 1. Please refer to Chapter 1.2 for a full description of materials and methods. 
2.3. Results 
2.3.1 Weight gain analysis 
 
In order to establish the effects of treatments on body weight and net weight gain, all experimental 
groups were weighed every third day (for the 2, 4 or 6 month experimental periods).  The data 
revealed that all groups gained weight equally over the 2 month treatment period; no significant 
differences were observed (Fig. 4.1.).   
 
Figure 4.1. Body weight and net weight gain in male Wistar rats following 2 months of treatment. A) 
Total body weight during the second month of treatment, n = 24. B) Weight gained over the second month 
of treatment, as calculated from the starting weight, n=24. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with a Bonferroni post-hoc test. PI – protease inhibitor, RSV - Resveratrol.  




After 4 months, PI-treated rats displayed decreased body weights (p < 0.05 vs. control; p < 0.001 vs. 
Jelly, Fig. 4.2.A).  In agreement, weight gain in the PI-treated group was also decreased compared to 
controls (p < 0.001 vs. Control; p < 0.001 vs. Jelly, Fig. 4.2.B). Rats receiving co-treatment of PI and 
RSV displayed increased weight gain when compared to PI-treated rats (Fig. 4.2.B). 
 
This pattern changed with prolonged treatment, i.e. 6 months PI treatment resulted in increased 
body weight and weight gain (***p < 0.001) when compared to control rats (Fig. 4.3.A and B). Rats 
receiving only jelly also displayed increased body weights and weight gain (**p < 0.01) when 
compared to the control group (Fig. 4.3.A and B). The same trend was observed in the body weight 
of the rats receiving PI in combination with RSV ($$p < 0.01) when compared to control rats.  Of note, 
PI treatment in combination with RSV did not display the increased body weight found with PI-
Figure 4.2. Body weight and net weight gain in male Wistar rats after 4 months of treatment. A) Total body 
weight over the fourth month of treatment: *p < 0.05 vs. control; @@@ < 0.001 vs. jelly, n = 12. B) Weight 
gained over the fourth month of treatment, as calculated from the starting weigh: ***p < 0.001 vs. control, 
@@@p < 0.001 vs. jelly, @p < 0.05 vs. PI+RSV, n=12. All results expressed as mean ± SEM, statistical analysis: 
one-way ANOVA with a Bonferroni post-hoc test. PI - protease inhibitor, RSV - Resveratrol. 
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Figure 4.3.  Body weight and net weight gain in male Wistar rats after 6 months of treatment. A) Total body 
weight over sixth month of treatment: ***p < 0.001 vs. control, **p < 0.01 vs. control, $$p < 0.01 vs. control, $p < 
0.05 vs. PI+RSV,  n = 6. B) Weight gained over 6 months of treatment, as calculated from the starting weigh: ***p 
< 0.001 vs. control, $$$p < 0.001 vs. PI+RSV, **p < 0.01 vs. control, n=6. All results expressed as mean ± SEM, 
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2.3.2 Analysis of triglyceride, cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) blood levels 
 
In order to establish the effects of each treatment on various biochemical markers which are 
commonly related to metabolic disturbances, blood samples were collected at the end of 2 and 4 
months of treatment for metabolite analysis.   No changes were observed in any of the blood 










Figure 4.4. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 2 months of 
treatment. A) No changes were observed in triglyceride levels, n = 6. B) No changes were observed in total 
cholesterol levels, n=6. C) No changes were observed in HDL levels, n=6. D) No changes were observed in 
LDL levels, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni 
post-hoc test. PI - protease inhibitor, RSV – resveratrol. 
 






Figure 4.5. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 4 months of 
treatment. A) No changes were observed in triglyceride levels, n = 6. B) No changes were observed in total 
cholesterol, n=6. C) No changes were observed in HDL levels, n=6. D) No changes were observed in LDL levels, 
n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. 
PI - protease inhibitor, RSV – Resveratrol. 
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 2.3.3 Analysis of mid-wall fractional shortening (MWFS) with the use of 
echocardiography 
 
In order to establish the effects of each treatment on systolic functioning, various functional 
parameters were assessed with echocardiography. These results were used to calculate mid-wall 
fractional shortening at the end of the2 and 4 month treatment periods.  We were not able to attain 
echocardiographical data at the 6 month time point due to logistical issues. 
No significant changes were observed in left ventricular functional parameters after 2 and 4 months 
of treatment, respectively (Tables 4.1.A&B). 
 
 
 Control Jelly PI PI+RSV 
LVEDD 6.0 ± 0.13 6.0 ± 0.09 6.6 ± 0.08 6.3 ± 0.11 
LVESD 2.9 ± 0.14 3.3 ± 0.14 3.6 ± 0.11 3.6 ± 0.14 
LVESPWT 1.9 ± 0.05 1.8 ± 0.05 1.9 ± 0.08 1.9 ± 0.08 
LVEDPWT 2.6 ± 0.07 2.4 ± 0.09 2.6 ± 0.11 2.4 ± 0.11 







 Control Jelly PI PI+RSV 
LVEDD 6.4 ± 0.13 6.6 ± 0.16 6.4 ± 0.16 6.8 ± 0.14 
LVESD 3.6 ± 0.12 3.5 ± 0.15 3.8 ± 0.14 3.8 ± 0.14 
LVESPWT 2.1 ± 0.07 2.0 ± 0.09 1.9 ± 0.04 1.9 ± 0.05 
LVEDPWT 2.6 ± 0.1 2.6 ± 0.09 2.4 ±  0.09 2.6 ± 0.08 





Table 4.1.A. Left ventricular parameters as measured with echocardiography after 2 months of treatment  
 
Table 4.1.B. Left ventricular parameters as measured with echocardiography after 4 months of treatment  
 
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
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Furthermore, no significant changes were observed in MWFS in all groups after 2 and 4 months of 








Figure 4.6. MWFS in male Wistar rats after 2 and 4 months of treatment. No significant changes were 
observed, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test. PI - protease inhibitor, RSV – Resveratrol. 
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2.3.4 Organ harvesting for the determination of treatment-induced anatomical changes 
 
In order to determine whether the treatments induced any gross anatomical changes, body weight 










Figure 4.8. Heart weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 
and 6 months of treatment. 2 months:*p < 0.05 vs. control, n=12. 4 months, n=12. 6 months: *p < 0.05 vs. 
control, @p < 0.05 vs. jelly, n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA 
with Bonferroni post-hoc test. PI - protease inhibitor, RSV – Resveratrol. 
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After 2 months, rats treated with PI in combination with RSV displayed decreased heart weight (p < 
0.05 vs. controls; Fig. 4.8.A). No significant changes were observed after 4 months of PI treatment 
(Fig. 4.8.B). After 6 months, PI-treated rats and rats co-treated with PI and RSV displayed increased 
heart weights (p < 0.05 vs. controls and Jelly; Fig. 4.8.C).   Left ventricular weight is increased in all 
groups in comparison to the control after 4 months of treatment (p < 0.05 vs. control). Conversely, 
right ventricular weight decreased for all groups after 4 months of treatment versus controls (p < 
0.05 vs. control, Fig. 4.10.A).    At the 6 month time point RSV co-treatment resulted in a decrease in 
left ventricular weight (p < 0.05) and corresponding increase in right ventricular weight (p < 0.05) 








Figure 4.10. Left and right ventricular weights normalized to total heart weight in male Wistar rats on the day 
of culling after 4 and 6 months of treatment, respectively. A) 4 months: *p < 0.05 vs. control, n=12. B) 6 
months: @p < 0.05 vs. jelly, n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test. PI - protease inhibitor, RSV - Resveratrol.  
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Liver weight normalized to right tibia length remained unchanged for all groups after 2, 4 and 6 








Figure 4.9. Liver weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 and 6 
months of treatment. 2 months: No significant changes were observed, n=12. 4 months: No significant changes were 
observed, n=12. 6 months:  No significant changes were observed, n=12. All results expressed as mean ± SEM, 
statistical analysis: one-way ANOVA with Bonferroni post-hoc testPI - protease inhibitor, RSV - Resveratrol. 
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After 4 months, retroperitoneal fat mass increased (p < 0.05) in rats co-treated with PI and RSV 
versus rats PI treated only (Fig. 4.11. 4 months).    After 6 months, rats that received only jelly 






Figure 4.11. Left and right ventricular weights normalized to heart weight in male Wistar rats on the day of 
culling after 4 and 6 months of treatment. A) 4 months: $p < 0.05 vs. PI+RSV, n=12. B) 6 months: *p < 0.05 vs. 
control, n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-
hoc test. PI - protease inhibitor, RSV – Resveratrol.  
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2.3.5 Analysis of mitochondrial respiration  
 
Mitochondrial oxygen consumption was assessed using oxygen electrodes (oxygraph) in sub-
sarcolemmal mitochondria after 4 and 6 months of PI treatment, respectively.   For the 4 month PI 
treatment period, State III respiration was impaired (p < 0.05 vs. control) in isolated mitochondria of 
PI-treated rats (glutamate and malate) (Table 4.2.A). Although State III respiration was diminished 
with PI treatment, the ADP:O ratio was increased indicating that it was respiring with greater 
efficiency.  The same impairment was observed in rats receiving the PI in combination with RSV (p < 
0.05 vs. control, Table 4.2.A) 
 
   CONTROL 
 
     JELLY 
 
       PI 
 
    PI+RSV 
Glutamate + Malate State III    200 ± 12   248 ± 75   150 ± 13*   154 ± 10* 
Glutamate + Malate State IV      56 ± 12     97 ± 26     64 ± 5     65 ± 6 
Glutamate + Malate RCR   2.53 ± 0.28  2.51 ± 0.21  2.37 ± 0.22  2.42 ± 0.19 
Glutamate + Malate ADP:O     2.0 ± 0.1    2.2 ± 0.4    2.7 ± 0.3*    2.7 ± 0.2* 
        
Malate + Pyruvate State III    151 ± 19   164 ± 19   166 ± 22   194 ± 17 
Malate + Pyruvate State IV      67 ± 10      55 ± 4     63 ± 8     68 ± 3 
Malate + Pyruvate State RCR     2.4 ± 0.32  2.95 ± 0.2  2.87 ± 0.4  2.92 ± 0.3 
Malate + Pyruvate State ADP:O   2.78 ± 0.31  2.61 ± 0.30  2.58 ± .029  2.15 ± 0.21 
        
Palmityl – Carnitine + Malate State III    178 ± 31   303 ± 105   172 ± 17   141 ± 7 
Palmityl – Carnitine + Malate State IV      90 ± 4     93 ± 23     83 ± 9     66 ± 5* 
Palmityl – Carnitine + Malate RCR   1.96 ± 0.3  3.14 ± 0.51    2.2 ± 0.34    2.3 ± 0.24 
Palmityl – Carnitine + Malate ADP:O   2.50 ± 0.39  1.95 ± 0.44  2.43 ± 0.21    2.9 ± 0.14 
        
Rotenone + Succinate State III    285 ± 53   287 ± 74   313 ± 71   388 ± 143 
Rotenone + Succinate State IV 146.7 ± 43   126 ± 26   193 ± 65     95 ± 25 
Rotenone + Succinate RCR   2.41 ± .59  2.29 ± 0.27  2.22 ± 0.78  2.69 ± 0.53 











Table 4.2.A. Function of isolated left ventricular sub-sarcolemmal mitochondria after 4 months of PI treatment. 
 *p < 0.05 vs. control, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test.  PI - protease inhibitor, RSV - Resveratrol. 
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No changes were observed in mitochondrial respiration following 6 months of PI treatment 
(Table4.2.B).  However, co-treatment of PI and RSV resulted in increased State III respiration (p < 
0.01 vs. control) (glutamate and malate) and a simultaneous decrease in ADP:O ratio (p <0.001 vs. 
control), indicating that respiration was impaired (Table 4.2.B).   When rotenone and succinate were 
used as substrates, isolated mitochondria from rats co-treated with PI and RSV displayed increased 
rates of State III respiration (p < 0.001) compared to controls (Table4.2.B). The ratio of ADP:O was 
however observed to be decreased (p < 0.001) when compared to controls, once again indicating 
impaired respiration (Table4.2.B).   Respiratory control ratios of isolated mitochondria from rats 
receiving PI in combination with RSV were increased (p < 0.05) when compared to rats receiving jelly 





CONTROL      JELLY        PI      PI+RSV 
Glutamate + Malate State III  176 ± 10  167 ± 13  161 ± 16  228 ±  17** 
Glutamate + Malate State IV    45 ± 5    48 ± 7    43 ± 4    57 ± 7 
Glutamate + Malate RCR 4.16 ± 0.46   3.7 ± 0.37   3.8 ± 0.28   4.2 ± 0.43 
Glutamate + Malate ADP:O 2.32 ± 0.13 2.47 ± 0.18 2.61 ± 0.26   1.8 ± 0.13** 
     
Malate + Pyruvate State III  129 ± 24  157 ± 16  193 ± 28  194 ± 8 
Malate + Pyruvate State IV    38 ± 2    40 ± 6    49 ± 7    46 ± 3 
Malate + Pyruvate State RCR 3.97 ± 0.31 4.14 ± 0.28 3.99 ± 0.13 4.25 ± 0.22 
Malate + Pyruvate State ADP:O 2.73 ± 0.19 2.66 ± 0.21 2.26 ± 0.28 2.08 ± 0.09 
     
Palmityl – Carnitine + Malate State III  150 ± 15  156 ± 8  183 ± 8  187 ± 18 
Palmityl – Carnitine + Malate State IV    42 ± 6    44 ± 5    51 ± 1    56 ± 6 
Palmityl – Carnitine + Malate RCR 3.87 ± 0.52 3.71 ± 0.39 3.61 ± 0.25   3.4 ± 0.15 
Palmityl – Carnitine + Malate ADP:O 2.78 ± 0.24   2.6 ± .14 2.21 ± 0.1 2.29 ± 0.32 
     
Rotenone + Succinate State III  209 ± 47  285 ± 10  201 ± 65  433 ± 16 
Rotenone + Succinate State IV    51 ± 16    74 ± 4    51 ± 17    87 ± 17 
Rotenone + Succinate RCR 5.03 ± 1.1 3.93 ± 0.28   4.0 ± 0.33 5.08 ± 0.2 
Rotenone + Succinate ADP:O 1.69 ± 0.23 1.41 ± 0.05 1.33 ± 0.04 0.93 ± 0.03 
Table 4.2.B. Function of isolated left ventricular sub-sarcolemmal mitochondria after 6 months of PI treatment. 
**p < 0.01 vs. Control; @p < 0.05 and @@p < 0.01 vs. Jelly; $p < 0.05 vs. PI, n=6. All results expressed as mean ± SEM, 











After 2 months of PI and RSV treatment there were no significant differences in bodyweight (Fig. 
4.1.A) or weight gains (Fig. 4.1.B) when compared to the control and PI groups, respectively.  This is 
not surprising since we did not observe any differences with sole PI treatment. After 4 months, the 
addition of RSV lessened PI-mediated effects on body weight and weight gain, i.e.  preventing the 
decrease in weights found with PIs (Fig. 4.2). After 6 months, RSV protected against PI-induced 
weight gain (Fig. 4.3).  What is the basis for such effects?  We are unclear regarding the precise 
mechanisms whereby RSV mediates its effects on weight gain, but the mitochondrion may indeed be 
a target.  It is our opinion that RSV supplementation likely increased SIRT1 activation and 
downstream targets such as AMPK and PGC-1 (refer Chapter 1) that can in turn increase 
mitochondrial number and mitochondrial respiration chain proteins to enhance intracellular 
metabolism (Ruderman et al, 2013).  This would then be expected to lower ROS production and 
potentially inhibit inflammation e.g. in adipose tissues.  
PPARs are a downstream target of AMPK and here PPAR is required for differentiation and 
maturation of adipose tissue (Fajas, 1999).  Of note, PPAR levels were decreased in peripheral 
adipose tissue (PAT) of HAART treated individuals (Kannisto, 2003) and thus it is a possibility that 
RSV may have offered protection against PI-induced decreases in PAT.  This may explain the effects 
of RSV after 4 months of treatment in our experimental model and is strengthened by the 
retroperitoneal fat pad weight data (Fig. 4.11).   However, PPAR also affects visceral adipose tissue 
(VAT) and decreased levels can lead to VAT hypertrophy.  This occurs through increased sterol 
synthesis and FFA uptake (Galescu et al, 2013).  We thus propose that at the 6 month time point 
RSV acted largely on VAT by increasing regulatory proteins such as SIRT1 and AMPK. However, 
additional mechanistic studies are required to evaluate the proposals here put forward. 
The levels of metabolites here studied did not significantly change after 2 and 4 months, respectively 
(Fig. 4.4 & 4.5). This was not surprising since we did not observe any changes in blood parameters 
with PI treatment alone.  However, these data differ from Gupta and colleagues (2012) who found 
hyperlipidemia and insulin resistance after only four weeks of PI treatment (Gupta et al, 2012). We 
propose that such difference may be dependent on the nature of experimental models employed, 
drug dosages and length of treatments.  Likewise, we did not find any significant differences for 
heart function by echocardiographic analysis (Table 4.1. A & B; Fig. 4.6).  Of note, RSV had no effect 
on PI-mediated increase in heart weight after 6 months of treatment (Fig. 4.8). More studies are 
required to confirm whether there is a hypertrophic response after 6 months of PI treatment and 
also whether it is physiological or pathological in nature.  




RSV elicited no significant effects on mitochondrial function following 4 months of PI treatment 
(Table 4.2.A). However, after 6 months  State III respiration was higher with RSV treatment 
compared to sole PI-treatment (oxidative substrates: malate and glutamate; succinate and 
rotenone), with a concomitant decrease in ADP/O ratios (Table 4.2.B). These results indicate that 
RSV exerts its effects at both complex I and III of the mitochondrial phosphorylation chain are 
involved.   These results are promising and confirm our earlier postulate that RSV is likely impacting 
on mitochondrial function to exert its beneficial effects in response to PI treatment.   
  




3.1. Inflammation as therapeutic target 
 
Decreased physical activity levels together with Westernised diets has played a strong role in the 
surge in cardio-metabolic diseases (Hall et al, 2011; Cheen and Van Gaal, 2014), with both obesity 
and type-2 diabetes constituting recognized risk factors for CVD development (Chen et al, 2012).  
Developing countries are also at risk in this instance (Chen et al, 2012), e.g. the International 
Diabetes Federation estimates that type-2 diabetes will increase by 98% in sub-Saharan countries by 
2025 (Sicree and Shaw, 2009; Chen et al, 2012) (Fig 5.1).   
Fig. 5.1. A) Global projections for diabetes: 2010–2030 (Chen et al, 2012); B) Global prevalence of HIV (Epidemiological 
facts sheet on HIV and AIDS, 2008). 
 
Moreover, this region contains roughly 90% of the HIV-infected individuals of the world (UNAIDS, 
2010) thus further adding to the overall burden of disease. In addition, there is cross-talk between 
these conditions with HIV a risk factor for CVD onset (Stevenson, 2003) as discussed before. Here PIs 
are strongly implicated in the development of cardio-metabolic complications as highlighted earlier 
in this thesis (Friis-Møller, 2010; Duong et al, 2001; Stevenson, 2010).   The underlying mechanisms 
whereby PIs exert damaging effects are not entirely clear, although mitochondria (Gardner et al, 
2013; Perez-Matute et al, 2013), inflammation (Arenas-Pinto, et al, 2015) (Capeau et al, 2013; 
Gardner et al, 2013), and ROS (Hwang et al, 2008; Shadel and Horvath, 2015; Andreyev et al, 2005) 
have been identified as potential mediators. 
Chronic inflammation in the vasculature is a risk factor and predictor of CVD (Arenas-Pinto et al, 
2015) as it can lead to a pro-atherogenic state (Grundy, 2011). The atherogenic state can cause 
plaque build-up and can eventually lead to ischemic tissue damage, increasing the risk for 
myocardial infarction or strokes (Grundy, 2011).  Inflammation is not the only cause for an 
atherogenic state and others include hyperglycemia, high blood pressure and elevated cholesterol 
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(Grundy, 2011). These generally work synergistically in ARV-treated HIV-positive patients and can 
negatively affect various tissues in the body (Zha et al, 2011).   
Focusing on inflammation, adipose tissues have emerged as more than storage depots and acting 
more like an endocrine organ (Kershaw and Flier, 2004), producing various peptides, proteins and 
cytokines termed ‘’adipokines’’ (Wozniak et al, 2009).  Of note, adipose tissue is also greatly affected 
by and also involved in the inflammation process (Lafontan, 2013; Nakamura et al, 2014). It is 
important to note that white adipose tissue, depending on its location, responds differently to 
inflammation (Andrade-Oliveira et al, 2015). It is grossly divided into two categories based on 
location, i.e. PAT and VAT, respectively (Kershaw and Flier, 2004).   VAT and PAT differ anatomically 
and also in terms of underlying physiology and molecular regulation.   For example, VAT has larger 
adipocytes, contains more macrophages and is richer in blood supply and more innervated than PAT 
(Ibrahim 2010). VAT adipocytes also express higher levels of β3-adrenergic receptors than PAT and 
this is put forward as a reason why VAT is more sensitive to catecholamine-induced lipolysis (Arner 
et al, 1990; Helmer et al, 1992).   The most important difference between PAT and VAT is, however, 
that the latter is associated with poor health outcomes (Nakamura et al, 2014) due to increased 
production of inflammatory markers. These markers include inflammatory cytokines such as 
Interleukin 6 (IL-6), Tumour Necrosis Factor alpha (TNF-α) and Monocyte Chemoattractant Protein-1 
(MCP-1) (Lafontan, 2013; Kershaw and Flier, 2004) that are released into the circulation causing 
systemic inflammation.  Chronically elevated levels of circulating inflammatory cytokines can lead to 
a pro-atherogenic state and CVD onset as discussed by Arenas-Pinto et al (2015).  
If inflammation is indeed a primary cause of the increased occurrence of adverse cardiovascular 
events in the PI-treated patients, then anti-inflammatory medication could potentially ameliorate 
such effects.  In light of this we explored Acetyl Salicylate (or better known as Aspirin) as an anti-
inflammatory co-treatment option.  It is the oldest pharmaceutical drug and is commonly used as an 
analgesic, anti-pyretic, anti-coagulant and part of the drug class termed non-steroidal anti-
inflammatories (NSAID) (Leaberry, 2010). It is believed to inhibit inflammation by inhibiting NF-kB, 
stopping the downstream events leading to inflammation.   In light of this, we propose that PI-
treatment together with Aspirin (Asp) supplementation can alleviate the adverse side-effects of PIs.  
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3.2. Materials and Methods 
 
Asp was purchased in the form of Disprin™ tablets (Reckitt &Benckiser Healthcare) (300 mg/tablet). 
The dosage received was 300 mg per kilogram body weight per day and all analyses and experiment 
performed were done as described in Chapter 1. Please refer to Chapter 1.2 for full description of 
materials and methods. 
3.3. Results 
3.3.1. Weight gain analysis 
 
In order to establish the effects of treatments on body weight and net weight gain, all experimental 
groups were weighed every third day (at 2, 4 and 6 months’ time-points).  Here our data reveal that 
no significant differences were found after 2 months of treatment (Fig. 6.1).  
 
 
Figure 6.1. Body weight and net weight gain in male Wistar rats following 2 months of PI treatment 
±ASP. A) Total body weight during the second month of treatment (n = 24). B) Weight gained over the 
second month of treatment, as calculated from the starting weight (n=24). All results expressed as mean ± 
SEM, statistical analysis: one-way ANOVA with a Bonferroni post-hoc test. PI – protease inhibitor, ASP – 
Aspirin.  
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However, after 4 months PI-treated rats displayed decreased body weights (p < 0.05 vs. control; p < 
0.001 vs. Jelly, Fig. 6.2.A).  Rats co-treated with PI and ASP also displayed decreased body weights (p 
< 0.01) compared to jelly controls (Fig. 6.2.A).  Similarly, weight gain also decreased (p < 0.001 vs. 
Control; p < 0.001 vs. Jelly) compared to controls in rats receiving only PI, and PI in combination with 























Figure 6.2. Body weight and net weight gain in male Wistar rats after 4 months of treatment. A) Total body 
weight during the fourth month of treatment: *p < 0.05 vs. control, @@@p < 0.001 vs. jelly, @@p < 0.01 vs. 
control,  n = 12. B) Weight gained over the fourth month of treatment, as calculated from the starting weight: 
***p < 0.001 vs. control, @@@p < 0.001 vs. jelly,  n=12. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with a Bonferroni post-hoc test. PI - protease inhibitor, ASP – Aspirin. 
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This pattern changed with prolonged treatment, i.e. PI treatment resulted in increased body weight 
after 6 months when compared to control rats (***p < 0.001) (Fig. 6.3. A). However, co-treatment 
(PI + ASP) resulted in decreased body weights ($p < 0.001) when compared to rats receiving only PI 
(Fig. 6.3. A). Rats treated with jelly did not display any significant increases in body weight after the 6 
month period (**p < 0.01) versus controls (Fig. 6.3. A). PI treatment led to significant increases in 
weight gain (***p < 0.001) when compared to control rats (Fig. 6.3. B). Interestingly, PI-treated rats 
receiving ASP prevented the PI-mediated increase in weight gain ($$$p < 0.001, Fig. 6.3. B). Rats 
receiving only jelly also displayed increased weight gain compared to control rats (**p < 0.01) and 





Figure 6.3.  Body weight and net weight gain in male Wistar rats after 6 months of treatment. A) Total body 
weight during sixth months of treatment: ***p < 0.001 vs. control, **p < 0.01 vs. control, $$$p < 0.001 vs. control, n 
= 6. B) Weight gained over 6 months of treatment, as calculated from the starting weight: ***p < 0.001 vs. control, 
$$$p < 0.001 vs. PI+ASP, **p < 0.01 vs. control, $$p < 0.01 vs. PI+ASP, n=6. All results expressed as mean ± SEM, 
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3.3.2. Analysis of triglyceride, cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) blood levels. 
 
In order to establish the effects of each treatment on various metabolites that are commonly related 
to metabolic disturbances, blood samples were collected at the end of 2 and 4 months of treatment 
























Figure 6.4. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 2 months of 
treatment. A) Triglyceride levels, n = 6. B) Total cholesterol levels, n = 6.  C) HDL levels, n=6. D) LDL levels, 
n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc 
test. PI - protease inhibitor, ASP – Aspirin. 
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Blood HDL, LDL and total cholesterol levels remained consistent for all groups after 4 months of 
treatment (Fig. 6.5. B, C and D). However, PI-treated rats receiving ASP exhibited an increase in 
circulating triglyceride blood levels (*p < 0.05) versus matched controls (Fig. 6.5. A).   Due to a lack of 
sample material, we were unable to perform similar analyses at the 6 month time point.  
 
  
Figure 6.5. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 4 months of treatment. A) 
Triglyceride levels: *p < 0.05 vs. control, n = 6. B) Total cholesterol levels, n=6. C) HDL levels, n=6. D) HDL levels, n=6. 
All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - 
protease inhibitor, ASP – Aspirin. 
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 3.3.3. Analysis of mid-wall fractional shortening (MWFS) with the use of 
echocardiography. 
 
In order to establish the effects of each treatment on systolic functioning, various functional 
parameters were assessed with echocardiography. These results were used to calculate mid-wall 
fractional shortening at the end of the 2 and 4 month treatment periods, respectively.  We were not 
able to attain echocardiographical data at the 6 month time point due to logistical issues and lack of 
animals.  These data show that no significant changes were observed in left ventricular functional 








 Control Jelly PI PI+ASP 
LVEDD 6.0 ± 0.13 6.0 ± 0.09 6.6 ± 0.08 6.2 ± 0.12 
LVESD 2.9 ± 0.14 3.3 ± 0.14 3.6 ± 0.11 3.1 ± 0.17 
LVESPWT 1.9 ± 0.05 1.8 ± 0.05 1.9 ± 0.08 1.8 ± 0.08 
LVEDPWT 2.6 ± 0.07 2.4 ± 0.09 2.6 ± 0.11 2.4 ± 0.1 







 Control Jelly PI PI+ASP 
LVEDD 6.4 ± 0.13 6.6 ± 0.16 6.4 ± 0.16 7.1 ± 0.09 
LVESD 3.6 ± 0.12 3.5 ± 0.15 3.8 ± 0.14 3.9 ± 0.12 
LVESPWT 2.1 ± 0.07 2.0 ± 0.09 1.9 ± 0.04 2.0 ± 0.07 
LVEDPWT 2.6 ± 0.1 2.6 ± 0.09 2.4 ±  0.09 2.6 ± 0.08 
R-R Interval 0.17 ± 0.004 0.18 ± 0.005 0.18 ± 0.003 0.18 ± 0.004 
Table 6.1.A. Left ventricular parameters as evaluated by echocardiography after 2 months of PI treatment  
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall Thickness; 









Table 6.1.B. Left ventricular parameters as determined by echocardiography after 4 months of PI treatment  
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall Thickness; 
LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
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In addition, no significant changes were observed in MWFS in all groups after 2 and 4 months of 




3.3.4. Organ harvesting for the determination of treatment-induced anatomical changes 
 
In order to determine whether the treatments induced any gross anatomical changes, body weight 
and various organs were harvested, weighed and normalized to tibial length.  
No significant changes were observed for total heart weight after 2 and 4 months of PI treatment 
(Figs. 6.8.A and 6.8.B).   However, after 6 months treatment the PI-treated rats displayed increased 
heart weights (p < 0.05 vs. controls and Jelly; Fig. 6.8.C).   Of note, this effect was lost with ASP 
treatment. 
Figure 6.6. MWFS in male Wistar rats after 2 and 4 months of treatment. No significant changes were 
observed, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test. PI - protease inhibitor, ASP – Aspirin. 











Figure 6.7. Heart weights normalized to tibia lengths in male Wistar rats after 2 and 4 months of 
treatment: *p < 0.05 vs. control, $p < 0.05 vs. jelly, n=6. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, ASP – Aspirin. 
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To gain additional insights, we also separately evaluated left and right ventricular weights. Here left 
ventricular weights were higher for all groups versus controls after 4 months of treatment (p < 0.05 
and p < 0.01 vs. control, Fig 6.10.A). Conversely, right ventricular weight decreased for all groups 
after 4 month of treatment (p < 0.05 and p < 0.01 vs. control, Fig. 6.10.A). No changes were observed 






Figure 6.8. Left and right ventricular weights normalized to total heart weight in male Wistar rats on the day 
of culling after 4 and 6 months of treatment, respectively. A) 4 months:*p < 0.05 and **p < 0.01 vs. control, 
n=12. B) 6 months: No significant changes were observed, n=12. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, ASP – Aspirin. 
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Liver weight normalized to right tibia length remained unchanged for all groups after 2, 4 and 6 







Figure 6.9. Liver weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 and 6 
months of treatment. 2 months: No significant changes were observed, n=12. 4 months: No significant changes 
were observed, n=12. 6 months:  No significant changes were observed, n=12. All results expressed as mean ± SEM, 
statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, ASP – Aspirin. 
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No changes were observed in retroperitoneal fat mass after 4 months of treatment (Fig. 6.11. 4 
months). However, rats fed with jelly cubes displayed increased retroperitoneal fat mass compared 
to control rats after 6 months (p < 0.05, Fig. 6.11. 6 months). 
  
Figure 6.10. Retroperitoneal fat mass  normalized to tibia lenght in male Wistar rats on the day of culling 
after 4 and 6 months of treatment. A) 4 months, n=12. B) 6 months: *p < 0.05 vs. control, n=12. All results 
expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease 
inhibitor, ASP – Aspirin.  
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3.3.5. Analysis of mitochondrial respiratory function  
 
We next determined mitochondrial (sub-sarcolemmal) oxygen consumption by employing oxygen 
electrodes (oxygraph) after 4 and 6 months of treatment, respectively.  
 
 
   CONTROL      JELLY         PI      PI+ASP 
Glutamate + Malate State III    200 ± 12  248 ± 75  150 ± 13*  230 ± 38$ 
Glutamate + Malate State IV      56 ± 12    97 ± 26    64 ± 5    71 ± 10 
Glutamate + Malate RCR   2.53 ± 0.28 2.51 ± 0.21 2.37 ± 0.22 3.35 ± 0.5 
Glutamate + Malate ADP:O     2.0 ± 0.1   2.2 ± 0.4   2.7 ± 0.3*   1.9 ± 0.2 
     
Malate + Pyruvate State III    151 ± 19  164 ± 19  166 ± 22  161 ± 15 
Malate + Pyruvate State IV      67 ± 10     55 ± 4    63 ± 8    58 ± 4 
Malate + Pyruvate State RCR     2.4 ± 0.32 2.95 ± 0.2 2.87 ± 0.4 2.79 ± 0.17 
Malate + Pyruvate State ADP:O   2.78 ± 0.31 2.61 ± 0.30 2.58 ± .029 2.59 ± 0.24 
     
Palmityl – Carnitine + Malate State III    178 ± 31  303 ± 105  172 ± 17  184 ± 27 
Palmityl – Carnitine + Malate State IV      90 ± 4    93 ± 23    83 ± 9    71 ± 10 
Palmityl – Carnitine + Malate RCR   1.96 ± 0.3 3.14 ± 0.51   2.2 ± 0.34 2.71 ± 0.37 
Palmityl – Carnitine + Malate ADP:O   2.50 ± 0.39 1.95 ± 0.44 2.43 ± 0.21 2.37 ± 0.28 
     
Rotenone + Succinate State III    285 ± 53  287 ± 74  313 ± 71  267 ± 6.61 
Rotenone + Succinate State IV 146.7 ± 43  126 ± 26  193 ± 65  163 ± 31 
Rotenone + Succinate RCR   2.41 ± .59 2.29 ± 0.27 2.22 ± 0.78 1.86 ± 0.26 





For the 4 month PI treatment period, state III respiration was impaired (p < 0.05 vs. control, Table 
6.2.A) in isolated mitochondria of PI-treated rats with glutamate and malate as substrates. Although 
state III respiration was diminished with PI treatment, the ADP:O ratio was increased indicating that 
it was respiring with greater efficiency.  With the addition of ASP to the PI treatment regime the 
opposite effect was observed. After 4 months, state III respiration in isolated mitochondria increased 
(p < 0.05 vs. control, Table 6.2.A) with glutamate and malate as substrates, although no difference in 




Table 6.2.A. Function of isolated left ventricular sub-sarcolemmal mitochondria after 4 months of PI treatment. 
 *p < 0.05 vs. control; $p < 0.05 vs. PI, n=6. All results expressed as mean ± SEM, statistical analysis: one-way 
ANOVA with Bonferroni post-hoc test.  PI - protease inhibitor, ASP – Aspirin. 
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No major changes were observed following 6 months of PI treatment (Table 6.2.B).  However, with 
the addition of ASP to the PI treatment regime, state IV respiration increased (p < 0.05 vs. PI, Table 
6.2.B) with glutamate and malate as substrates. State IV respiration also increased (p < 0.05 vs. 









  CONTROL      JELLY         PI      PI+ASP 
Glutamate + Malate State III  176 ± 10  167 ± 13  161 ± 16  246 ± 44 
Glutamate + Malate State IV    45 ± 5    48 ± 7    43 ± 4    94 ± 12$ 
Glutamate + Malate RCR 4.16 ± 0.46   3.7 ± 0.37   3.8 ± 0.28 2.95 ± 0.76 
Glutamate + Malate ADP:O 2.32 ± 0.13 2.47 ± 0.18 2.61 ± 0.26 1.83 ± 0.24 
     
Malate + Pyruvate State III  129 ± 24  157 ± 16  193 ± 28  179 ± 34 
Malate + Pyruvate State IV    38 ± 2    40 ± 6    49 ± 7    66 ± 25 
Malate + Pyruvate State RCR 3.97 ± 0.31 4.14 ± 0.28 3.99 ± 0.13   3.6 ± .91 
Malate + Pyruvate State ADP:O 2.73 ± 0.19 2.66 ± 0.21 2.26 ± 0.28 2.56 ± 0.51 
     
Palmityl – Carnitine + Malate State III  150 ± 15  156 ± 8  183 ± 8  211 ± 29 
Palmityl – Carnitine + Malate State IV    42 ± 6    44 ± 5    51 ± 1  111 ± 25* 
Palmityl – Carnitine + Malate RCR 3.87 ± 0.52 3.71 ± 0.39 3.61 ± 0.25   2.4 ± 0.53 
Palmityl – Carnitine + Malate ADP:O 2.78 ± 0.24   2.6 ± .14 2.21 ± 0.1   2.1 ± 0.27 
     
Rotenone + Succinate State III  209 ± 47  285 ± 10  201 ± 65  287 ± 15 
Rotenone + Succinate State IV    51 ± 16    74 ± 4    51 ± 17    76 ± 6 
Rotenone + Succinate RCR 5.03 ± 1.1 3.93 ± 0.28   4.0 ± 0.33   3.8 ± 0.23 
Rotenone + Succinate ADP:O 1.69 ± 0.23 1.41 ± 0.05 1.33 ± 0.04   1.4 ± 0.07 
Table 6.2.B. Function of isolated left ventricular sub-sarcolemmal mitochondria after 6 months of PI treatment. 
*p < 0.05 vs. Control; $p < 0.05 vs. PI, n=6. All results expressed as mean ± SEM, statistical analysis: one-way 
ANOVA with Bonferroni post-hoc test.  PI - protease inhibitor, ASP – Aspirin. 





PIs are known to cause serious side-effects such as CVD onset (Friis moller et al, 2010).  As 
mitochondrial dysregulation and inflammation are implicated in this process, this study evaluated 
whether Asp could ameliorate PI-induced side-effects.   Our data reveal that after 4 months PI 
treatment, Asp co-treatment was unable to inhibit weight loss as was the case for RSV (Fig. 6.2).  
This suggests that the mitochondrion rather than inflammation is implicated in PI-induced wasting at 
this time point.  However, at the 6 month time point ASP (like RSV) protected against the PI-induced 
weight gain suggesting that both mitochondria and systemic inflammation may be involved 
attenuating PI-induced weight gain (Fig. 6.3).   More studies are, however, required to confirm these 
claims. 
Blood metabolite profiles (Fig. 6.4 & 6.5) and echocardiographical analyses (Table 6.1. A & B; Fig. 6.6) 
once again did not show any differences between groups, which remains difficult to explain. Heart 
weights displayed a strange trend, i.e. all treatment groups exhibited increased left ventricular 
weights/heart weight and decreased right ventricular weights/heart weight ratios after 4 months 
versus the control group (Fig. 6.8.A). This is difficult to explain especially since the body weights of 
these groups differed significantly. After 6 months ASP co-treatment was effective at blunting the PI-
mediated increase in heart weight (Fig. 6.7).  These results indicate that inflammation may play a 
role to limit the hypertrophic response in our experimental system, although more research is 
required to confirm this. 
After 4 months of co-treatment with ASP, State III respiration was significantly increased when 
compared to sole PI treatment and resulted in no alterations in the ADP:O ratio (Table 6.2.A).  After 
6 months State IV respiration was increased in the ASP-treated group when glutamate + malate and 
palmitoyl-carnitine + malate were used as substrates, respectively (Table 6.2.B).   Thus these data 
suggest that ASP may have detrimental effects after 6 months by increasing proton leak.  
Alternatively, higher proton leak may be an adaptive step to decrease ROS generation as discussed 
before (Miro et al, 2004)).   However, more detailed research is required to further investigate these 
interesting possibilities.  
  




4.1. ROS as therapeutic target 
 
The development of CVD in ARV-treated patients is multifactorial (Chastain et al, 2015) as discussed 
in the previous chapters of this thesis (Friis moller et al, 2010).  PIs in particular can elicit damaging 
effects that typically include metabolic disturbances, lipodystrophy and the development of type-2 
diabetes (Friis moller et al, 2010; Worm et al, 2010).   Such side-effects are of course well-described 
risk factors for CVD onset (Friis moller et al, 2010).   AS the focus of this chapter is on a strategy 
against oxidative stress, it is crucial for cells to initiate protective mechanisms against the damaging 
effects of ROS.  This is usually achieved by antioxidant surveillance systems, e.g. superoxide 
dismutase systems (SOD) and glutathione (Alleman et al, 2014). However, if ROS generating capacity 
exceeds the antioxidant protective systems this will result in excess ROS with detrimental outcomes 
(Reiche and Kaminami, 2014). 
It has been proposed that PIs can act on mitochondrial to increase ROS production (Reyskens and 
Essop, 2013). However, it remains unclear exactly how this occurs, although increased ROS levels 
could eventually lead to systemic inflammation, increased lipodystrophy and a higher risk for CVD 
onset. Thus a useful therapeutic strategy would be to supplement PI treatment with dietary 
antioxidants to potentially combat increased ROS levels.   For our study, we focused on ascorbic acid, 
or better known as Vitamin C (VitC), a common naturally occurring organic compound with 
antioxidant properties (Iqbal et al, 2004).  VitC reacts with and reduces all physiologically relevant 
radicals and oxidants (Carr and Frei, 1999) making it an excellent antioxidant for our experimental 
setting.   Moreover, HIV-positive patients display decreased VitC levels making our choice even more 
meaningful (Stephensen et al, 2006).   In addition, it is relatively cheap and easy to access and would 
therefore be a perfect therapeutic option to employ in resource-deprived settings.  In light of this, 
we propose VitC supplementation may ameliorate PI-induced cardio-metabolic complications in our 
experimental model. 
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4.2. Materials and Methods 
VitC was purchased in the form of powdered sodium ascorbate (Enhance, Compli-Med) and the 
dosage employed was 300 mg per kilogram body weight per day. All analyses and experiments were 
performed as described in Chapter 1. Please refer to Chapter 1.2 for full description of materials and 
methods. 
4.3. Results 
 4.3.1. Weight gain analysis 
 
In order to establish the effects treatment on body weight and net weight gain, all experimental 
groups were weighed every third day (for 2, 4 and 6 months treatment, respectively).   The data 
revealed that all groups gained weight equally over the 2 month treatment period; no significant 
differences were observed (Fig. 7.1).   
Figure 7.1. Body weight and net weight gain in male Wistar rats following 2 months of 
treatment. A) Total body weight during the second month of treatment, n = 24. B) Weight 
gained over the second month of treatment, as calculated from the starting weight, n=24. All 
results expressed as mean ± SEM, statistical analysis: one-way ANOVA with a Bonferroni post-
hoc test. PI – protease inhibitor, VitC – vitamin C.  
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After 4 months, PI-treated rats displayed decreased body weights compared to controls (p < 0.05 vs. 
control; p < 0.001 vs. Jelly; Fig. 7.2.A). Similarly, weight gain was also decreased compared to 
controls (p < 0.001 vs. Control; p < 0.001 vs. Jelly; Fig. 7.2.B). The addition of VitC to the PI treatment 
normalized body weights (p < 0.001) and weight gains (p < 0.01) when compared to the rats 
receiving PI treatment alone (Fig. 7.2). 
 
Figure 7. 2. Body weight and net weight gain in male Wistar rats after 4 months of treatment. A) Total body 
weight over the fourth month treatment period: *p < 0.05 vs. control, @@@p < 0.001 vs. jelly, $$$p < 0.001 vs. 
PI+VitC, n = 12. B) Weight gained over the fourth month treatment period, as calculated from the starting 
weight: ***p < 0.001 vs. control; @@@p < 0.001 vs. jelly, $$p < 0.01 vs. PI+VitC, n=12. All results expressed as 
mean ± SEM, statistical analysis: one-way ANOVA with a Bonferroni post-hoc test. PI - protease inhibitor, VitC 
– vitamin C. 
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However, this pattern changed with prolonged treatment with increased body weight found after 6 
months (***p < 0.001) with protease inhibitors only when compared to control rats (Fig. 7.3.A). Rats 
receiving jelly also displayed increased body weights (**p < 0.01) when compared to control rats 
(Fig. 7.3.A). Rats receiving VitC in their PI treatment regime also exhibited increased body weights 
($$p < 0.01) when compared to controls (Fig. 7.3.A), but did not display decreased weight gain (p < 
0.05) compared to rats receiving only PI (Fig. 7.3.B) 
 
 
Figure 7.3.  Body weight and net weight gain in male Wistar rats after 6 months of treatment. A) Total body 
weight over sixth months of treatment: **p < 0.01 vs. control, $$p < 0.01 PI, ***p < 0.001 vs. control, n = 6. B) 
Weight gained over 6 months of treatment, as calculated from the starting weight: ** p < 0.01 vs. jelly, ***p < 
0.001 vs. control, $p < 0.05 vs. PI+VitC,  n=6.  All results expressed as mean ± SEM, statistical analysis: one-way 
ANOVA with a Bonferroni post-hoc test. PI - protease inhibitor, VitC – vitamin C. 
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4.3.2. Analysis of triglyceride, cholesterol, low-density lipoprotein (LDL) and high-density 
lipoprotein (HDL) blood levels 
 
In order to establish the effects of treatments on various markers that are commonly related to 
metabolic disturbances, blood samples were collected at the end of 2 and 4 months of treatment, 
respectively, for metabolite analysis.  Due to lack of samples, these assays were not performed for 
the 6 month treatment group.   After 2 months, no changes were observed in circulating triglyceride 
and HDL blood levels for all treatment groups (Fig. 7.4. A and C). However, PI-treated rats also 
receiving VitC displayed increased total cholesterol (p < 0.05) and LDL (p < 0.01) levels when 







Figure 7.4. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 2 months of 
treatment. A) No changes were observed in triglyceride levels in any of the treatment groups, n = 6. B) Total 
cholesterol: *p < 0.05 vs. control, n=6. C) No changes were observed in the HDL levels, n=6. D) LDL:  **p < 0.01 
vs. control, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni 
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HDL, triglycerides and total cholesterol blood levels remained consistent for all groups after 4 
months of PI treatment (Fig. 7.5. A, B and C).  However, LDL levels were increased (p < 0.05) in PI- 









Figure 7.5. Triglyceride, cholesterol, LDL and HDL blood levels in male Wistar rats after 4 months of treatment. A) 
No changes were observed in triglyceride levels, n = 6. B) No changes were observed in total cholesterol, n=6. C) No 
changes were observed in HDL levels in any of the treatment groups, n=6. D) LDL: *p < 0.05 vs. PI, n=6. All results 
expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease 
inhibitor, VitC – vitamin C. 
$ 
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 4.3.3. Analysis of mid-wall fractional shortening (MWFS) with the use of 
echocardiography 
 
In order to establish the effects of each treatment on systolic functioning, various functional 
parameters were assessed with echocardiography. These results were used to calculate mid-wall 
fractional shortening at the end of the 2 and 4 month treatment periods.  We were not able to attain 
echocardiographical data at the 6 month time point due to logistical issues. 
 
No significant changes were observed in left ventricular functional parameters after 2 and 4 months 
of treatment, respectively. 
 
 
    Control       Jelly          PI     PI+VitC 
LVEDD   6.0 ± 0.13   6.0 ± 0.09   6.6 ± 0.08   6.2 ± .13 
LVESD   2.9 ± 0.14   3.3 ± 0.14   3.6 ± 0.11   3.5 ± 0.16 
LVESPWT   1.9 ± 0.05   1.8 ± 0.05   1.9 ± 0.08   1.8 ± 0.05 
LVEDPWT   2.6 ± 0.07   2.4 ± 0.09   2.6 ± 0.11   2.3 ± 0.06 





 Control Jelly PI PI+VitC 
LVEDD 6.4 ± 0.13 6.6 ± 0.16 6.4 ± 0.16 6.8 ± 0.11 
LVESD 3.6 ± 0.12 3.5 ± 0.15 3.8 ± 0.14 3.8 ± 0.15 
LVESPWT 2.1 ± 0.07 2.0 ± 0.09 1.9 ± 0.04 2.0 ± 0.06 
LVEDPWT 2.6 ± 0.1 2.6 ± 0.09 2.4 ±  0.09 2.5 ± 0.07 










Table 7.1.B. Echocardiographic results after 4 months of treatment  
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
Table 7.1.A. Echocardiographic results after 2 months of treatment 
LVEDD – Left Ventricular End Diastolic Diameter; LVESD – Left Ventricular End Systolic Diameter; LVESPWT – Left Ventricular End Systolic Posterior Wall 
Thickness; LVEDPWT – Left Ventricular End Diastolic Posterior Wall Thickness 
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Moreover, no significant changes were observed in MWFS in all groups after 2 and 4 months of 






Figure 7.6. MWFS in male Wistar rats after 2 and 4 months of treatment. No significant changes were 
observed, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with 
Bonferroni post-hoc test. PI - protease inhibitor, VitC – vitamin C. 
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4.3.4. Organ harvesting for the determination of treatment-induced anatomical changes 
 
In order to determine whether the treatments induced any gross anatomical changes, body weight 
was determined as well as weights of various organs harvested - normalized to tibial length.   No 
significant changes were observed after 2 months of PI treatment (Fig. 7.8.A). However, rats 
receiving PI in combination with VitC did display decreased heart weights (p < 0.05) compared to 
control rats (Fig. 7.8.A). No significant changes were observed after 4 months of treatment (Fig. 
7.8.B), while PI-treated rats displayed increased heart weights after 6 months (p < 0.05 vs. controls 
and Jelly; Fig. 7.8.C). 
 
  
Figure 7.7. Heart weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 
and 6 months of treatment. 2 months: *p < 0.05 vs. control, n=12. 4 months: No significant changes were 
observed, n=12. 6 months:  *p < 0.05 vs. control, n=12. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, VitC – vitamin C. 
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After 4 months, right ventricular weight was lower in all groups versus the control (Fig. 7.10.A), 
while left ventricular weight increased in parallel for all groups (p < 0.05 and p < 0.01 vs. control, 










Figure 7.8. Left and right ventricular weights normalized to total heart weight in male Wistar rats on the day 
of culling after 4 and 6 months of treatment, respectively. A) 4 months:*p < 0.05 and **p < 0.01 vs. control, 
n=12. B) 6 months: No changes were observed in ventricular weights, n=12. All results expressed as mean ± SEM, 
statistical analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, VitC – vitamin C.  
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We next evaluated liver weights and retroperitoneal fat mass.  Here liver weights remained 







Figure 7.9. Liver weights normalized to right tibia length in male Wistar rats on the day of culling after 2, 4 and 6 
months of treatment. 2 months: No significant changes were observed, n=12. 4 months: PI vs. PI+VitC, $p < 0.05, 
n=12. 6 months:  No significant changes were observed, n=12. All results expressed as mean ± SEM, statistical 
analysis: one-way ANOVA with Bonferroni post-hoc test. PI - protease inhibitor, VitC – vitamin C. 
 
Stellenbosch University  https://scholar.sun.ac.za
104 
 
For fat mass assessments, no significant changes were observed after 4 months of PI treatment (Fig. 
7.10.A).  However, rats that were fed jelly cubes displayed increased retroperitoneal fat mass after 6 





Figure 7.10. Left and right ventricular weights normalized to heart weight in male Wistar rats on the day of 
culling after 4 and 6 months of treatment. A) 4 month: No changes were observed, n=12. B) 6 months: *p < 
0.05 v. jelly, n=12. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni 
post-hoc test. PI - protease inhibitor, VitC – vitamin C.  
 
* 
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 4.3.5. Analysis of mitochondrial respiration  
 
Mitochondrial oxygen consumption was next assessed using oxygen electrodes (oxygraph) in sub-
sarcolemmal mitochondria after 4 and 6 months of PI treatment, respectively.  
 
For the 4 month treatment period, state III respiration was impaired in isolated mitochondria of PI-
treated rats with glutamate and malate as substrates (p < 0.05 vs. control, Table 7.2.A). Although 
state III respiration was diminished with PI treatment, the ADP:O ratio was increased (p < 0.05 vs 
control, Table 7.2.A) indicating that it was respiring with greater efficiency.  When malate and 
pyruvate served as substrates, isolated mitochondria from rats receiving PI+VitC displayed higher 
respiratory control ratios (p < 0.05 vs. jelly, Table 7.2.A)  when compared to rats receiving only jelly. 
 
   CONTROL       JELLY        PI      PI+VitC 
Glutamate + Malate State III    200 ± 12  248 ± 75  150 ± 13*    180 ± 22 
Glutamate + Malate State IV      56 ± 12    97 ± 26    64 ± 5      72 ± 8 
Glutamate + Malate RCR   2.53 ± 0.28 2.51 ± 0.21 2.37 ± 0.22   2.52 ± 0.21 
Glutamate + Malate ADP:O     2.0 ± 0.1   2.2 ± 0.4   2.7 ± 0.3*     1.8 ± 0.3 
     
Malate + Pyruvate State III    151 ± 19  164 ± 19  166 ± 22    137 ± 11 
Malate + Pyruvate State IV      67 ± 10     55 ± 4    63 ± 8      59 ± 5 
Malate + Pyruvate State RCR     2.4 ± 0.32 2.95 ± 0.2 2.87 ± 0.4   2.37 ± 0.15@ 
Malate + Pyruvate State ADP:O   2.78 ± 0.31 2.61 ± 0.30 2.58 ± .029     3.0 ± 0.23 
     
Palmityl – Carnitine + Malate State III    178 ± 31  303 ± 105  172 ± 17 162.7 ± 19 
Palmityl – Carnitine + Malate State IV      90 ± 4    93 ± 23    83 ± 9      69 ± 11 
Palmityl – Carnitine + Malate RCR   1.96 ± 0.3 3.14 ± 0.51   2.2 ± 0.34   2.58 ± 0.5 
Palmityl – Carnitine + Malate ADP:O   2.50 ± 0.39 1.95 ± 0.44 2.43 ± 0.21   2.61 ± 0.33 
     
Rotenone + Succinate State III    285 ± 53  287 ± 74  313 ± 71    254 ± 22 
Rotenone + Succinate State IV 146.7 ± 43  126 ± 26  193 ± 65    204 ± 26 
Rotenone + Succinate RCR   2.41 ± .59 2.29 ± 0.27 2.22 ± 0.78   1.32 ± 0.19 







Table 7.2.A. Function of isolated left ventricular sub-sarcolemmal mitochondria after 4 months of PI treatment. 
 *p < 0.05 vs. control; @p < 0.05 vs. jelly, n=6. All results expressed as mean ± SEM, statistical analysis: one-way 
ANOVA with Bonferroni post-hoc test.  PI - protease inhibitor. 
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For the 6 month time point, State III respiration increased (malate and pyruvate as substrates) (p 






 CONTROL      JELLY       PI      PI+VitC 
Glutamate + Malate State III  176 ± 10  167 ± 13  161 ± 16  204 ± 13 
Glutamate + Malate State IV    45 ± 5    48 ± 7    43 ± 4    54 ± 6 
Glutamate + Malate RCR 4.16 ± 0.46   3.7 ± 0.37   3.8 ± 0.28 3.94 ± 0.44 
Glutamate + Malate ADP:O 2.32 ± 0.13 2.47 ± 0.18 2.61 ± 0.26   2.0 ± 0.14 
     
Malate + Pyruvate State III  129 ± 24  157 ± 16  193 ± 28  218 ± 18* 
Malate + Pyruvate State IV    38 ± 2    40 ± 6    49 ± 7    54 ± 9 
Malate + Pyruvate State RCR 3.97 ± 0.31 4.14 ± 0.28 3.99 ± 0.13   4.5 ± 0.74 
Malate + Pyruvate State ADP:O 2.73 ± 0.19 2.66 ± 0.21 2.26 ± 0.28 1.89 ± 0.17 
     
Palmityl – Carnitine + Malate State III  150 ± 15  156 ± 8  183 ± 8  173 ± 28 
Palmityl – Carnitine + Malate State IV    42 ± 6    44 ± 5    51 ± 1    61 ± 13 
Palmityl – Carnitine + Malate RCR 3.87 ± 0.52 3.71 ± 0.39 3.61 ± 0.25   3.0 ± 0.36 
Palmityl – Carnitine + Malate ADP:O 2.78 ± 0.24   2.6 ± .14 2.21 ± 0.1 2.48 ± 0.36 
     
Rotenone + Succinate State III  209 ± 47  285 ± 10  201 ± 65  235 ± 22 
Rotenone + Succinate State IV    51 ± 16    74 ± 4    51 ± 17    64 ± 5 
Rotenone + Succinate RCR 5.03 ± 1.1 3.93 ± 0.28   4.0 ± 0.33   3.7 ±0.07 
Rotenone + Succinate ADP:O 1.69 ± 0.23 1.41 ± 0.05 1.33 ± 0.04 1.72 ± 0.16 
Table 7.2.B. Function of isolated left ventricular sub-sarcolemmal mitochondria after 6 months of PI treatment. 
*p < 0.05 vs. control, n=6. All results expressed as mean ± SEM, statistical analysis: one-way ANOVA with Bonferroni 
post-hoc test.  PI - protease inhibitor. 
 





HIV/AIDS has become a global health concern over the past decade.  Although HAART is successfully 
being rolled out, it can also trigger unwanted side-effects such as cardio-metabolic complications 
(Friis-Møller, 2010; Miro et al, 2010).  As ROS are implicated in this process, we employed VitC as an 
antioxidant in our experimental setting.   After 4 months of treatment, VitC significantly ameliorated 
the effects of sole PI treatment on body weight and weight gain (Fig. 7.2. A & B).  This may be 
explained as we have done previously, i.e. the initial weight loss occurring due to increased ROS and 
that although VitC possesses additional metabolic benefits (Levine et al, 1999), most of its benefits 
accrue due to antioxidant capacity, e.g. decreasing oxidative DNA and/or protein damage, LDL 
oxidation and lipid peroxidation (Levine et al, 1999).  
 
It is our postulate that VitC protected against PI-mediated mitochondrial ROS production.  This is in 
keeping with the notion that PI treatment can lead to mitochondrial dysfunction (direct or indirect) 
that in turn enhances mitochondrial ROS production (Reyskens and Essop, 2013).  Increased ROS 
production can lead to serious intracellular damaging effects as previously discussed. In addition, 
Pérez-Matute and colleagues (2013) postulated that this may cause PI-mediated lipodystrophy since 
PAT and VAT possess different amounts of mitochondria (Pérez-Matute et al, 2013).  They propose 
that PAT (contains more mitochondria) can produce more ROS than VAT thereby leading to greater 
oxidative stress, inflammation, and apoptosis to decrease peripheral fat mass (Zha et al, 2011). 
Mitochondrial dysfunction seem like a plausible cause since Shikuma and colleagues (2001) also 
found decreased mitochondrial DNA in subcutaneous fat of HIV patients with ARV-induced 
peripheral lipoatrophy, when compared to HIV positive controls (Shikuma et al, 2001). This could 
possibly occur due to the effects of ROS on the mitochondria or due to direct effects of PI treatment 
on mitochondria. We therefore postulate that excess ROS lead to damage and subsequent cell death 
in especially peripheral adipose tissues and that VitC inhibited this from occurring through its 
oxidant scavenging potential.  
 
After 6 months of treatment the weight results resembled that of the other interventions, i.e. 
lowering PI-mediated body weight and weight gains (Fig. 7.3).  This suggests that VitC may be 
effective against both the early weight loss (4 month time point) and following weight gain (6 month 
time point).  An alternative mechanism whereby VitC may achieve its effects could be by increasing 
thyroid hormone production. In support, Feuring and colleagues (2011) fed guinea-pigs a diet 
containing low or VitC doses for 6-8 weeks (Feuring et al, 2011).  Here they found a significant 
increase in body weight with high dose supplementation together with a significant increase in liver 
mitochondrial number. Moreover, these mitochondria were also morphologically smaller compared 
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to the low VitC dose group (Feuring et al, 2011). VitC supplementation can also lead to increased 
serum thyroxine levels (Degkwitz and Bodeker, 1993) that can increase mitochondrial oxygen 
consumption (Gross, 1971) and ATP production (Seitz et al, 1985). This can occur directly via its 
binding to target sites on the mitochondrial inner-membrane (Sterling et al, 1978; Azimova et al, 
1984).  Moreover, relatively low clinical levels of thyroid hormone have been found in HIV-positive 
patients on HAART (Madeddu et al, 2006). Thus these data support a wider role for VitC than a mere 
antioxidant, although more clinical studies are required to test the veracity of such early findings. 
 
Organ weights followed a similar trend as with RSV and ASP treatments, i.e. after 2 months PI + VitC 
total heart weights were lower versus the control group (Fig. 7.7.A).  No differences in total heart 
weights were observed after 4 months of treatment (Fig. 7.7.B). However, the addition of VitC to PI 
treatment was effective at inhibiting the PI-mediated increase in heart weight after 6 months (Fig. 
7.7.C).  
 
After 4 months of VitC treatment, cholesterol and LDL levels were increased versus controls (Fig. 
7.4), while after 6 months only LDL levels remained elevated (Fig. 7.5).  This finding is difficult to 
explain as it is contradictory to what was expected, e.g. VitC supplementation has been implicated in 
decreasing plasma LDL levels (Ginter et al, 1969; Ginter et al, 1970; Ginter et al, 1973).   There is no 
information in the literature to support our findings and we therefore speculate the involvement of 
reverse feedback regulation of sterol synthesis.  Sterol synthesis is regulated via 3-hydroxy-3-methyl-
glutaryl-CoA reductase (HMG-CoA reductase) (Brown and Goldstein, 1980) and the latter catalyzes 
the rate-limiting step in the mevalonate pathway that regulates cholesterol synthesis.  We postulate 
that this pathway is likely to be activated in our model, i.e. rats treated with PI + VitC.    However, 
further studies are required to investigate such proposals.  In addition, blood metabolites could also 
be analyzed at more regular time points during the treatment regimen to assess whether cholesterol 
levels fluctuate as would be expected when feedback regulation is involved.  
 
After 4 months of treatment, VitC ameliorated the PI-mediated decrease in State III respiration when 
glutamate and malate was used as substrates, implying that PI-induced effects may occur due to 
excessive ROS production (Table 7.2.A).  VitC could thus have normalized mitochondrial respiration 
by scavenging ROS, suggesting that our findings RSV and ASP were not due to antioxidant effects.  









Our study reveals that PI treatment triggers detrimental effects on body weight gain and 
mitochondrial respiration function.  However, we did not observe significant changes in terms of 
dyslipidemia and heart function. Thus our newly established in vivo model of PI treatment 
recapitulates a moderate, and early stage in the progression of PI-mediated cardio-metabolic 
complications.  These data therefore identify the earlier changes in this timeline thus offering 
attractive therapeutic targets, especially at the mitochondrial level. The interventions employed 
generally showed promise in this regard by targeting body weight changes and attenuating 
mitochondrial dysfunction.  VitC treatment resulted in altered lipid levels that may prove damaging 
in the long run and therefore RSV and ASP emerge as co-treatments that offer promise for HIV-
positive patients.  
Limitations 
 
There are species-specific differences in terms of metabolic pathways, e.g. the enzyme responsible 
for acetyl salicylate metabolism where humans use Cytochrome P450 2A (CYP2A) while rats rely on 
Cytochrome P450 3A (CYP3A).  This is problematic as CYP3A is also used for the metabolism of both 
lopinavir and ritonivar and potentially result in drug-drug interactions that would not be the case in 
humans.  In addition, as rats here employed were not HIV positive, we were unable to study the 
effects of the virus in combination with the PI treatment. 
 
The number of rats per cage could also have a dramatic effect on weight gain, where the strict 
hierarchy could result in differences between weight gains.  A further potential limiting factor is that 
steady state concentrations of PIs were not tested in this study. This would have been a good 
method to assess whether dosages reached the same plasma levels as for HIV-positive individuals on 
Alluvia™ treatment, while also assessing the accuracy of the BSA dose translation formula in our 
setting.  Our initial plan was to use liquid chromatography/mass spectrometry to assess circulating 
lopinavir levels but we required purified compound for this purposes. We attempted to source this 
from local pharmaceutical companies but did not receive any cooperation and were thus 
unsuccessful in this regard.  
 
The fact that we could perform all the techniques at all of the experimental time points is a 
limitation.  However, we are of the opinion that this is not detrimental in proving our hypothesis for 
the following reasons: a) as the echocardiography data show no differences at 2 or 4 months 
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treatment indicates that PIs did not affect heart function during the early stages of this experiment; 
and b) recording the echocardiography data together with blood metabolite levels confirmed the 
lack of risk for metabolic syndrome after 2 and 4 months, respectively.   
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Mitochondrial Respiration Buffer Constituents and Preparation 
 
1. Buffer A 
Constituents: 100 mM KCl, 50 mM mops, 5.0 mM MgSO4, 1.0 mM EGTA, and 1.0 mM ATP 
To prepare: 
15 ml 2.0 M Kcl 
15 ml 1.0 M mops 
15 ml 0.1 M MgSO4.7H2O 
3 ml 0.1 M EGTA 
The solution was then made up to 300 ml with ddH2O where after 0.183 g ATP (Sigma, 
A7699) was added. The final solution was made up to pH 7.4 with 10 N KOH. 
2. Buffer B 
 
Buffer A with 2 mg/ml BSA (fatty-acid free) 
 
3. Respiration Buffer 
 
Constituents:  2.0 M KCl, 1.0 M mops, 0.1 M MgSO4.7H20, 0.1 M EGTA, 2xKM*,  
100 mM KH2PO4, 5% BSA 
*200mM KCl and 100 mM mops 
To prepare: 
250 ml 2xKM 
25 ml 0.1 M EGTA 
10 ml 5% BSA (fatty acid free) 
Solution was adjusted to pH 7.4 with 10 N KOH and made up to 500 ml with ddH2O. 




5 ml EGTA was added to 495 ml KM buffer (EGTA final volume – 1mM) 
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